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ABSTRACT 
 
In this experiment, a 3D microfluidic chip is designed and fabricated to replicate the 
function of the placenta. This sort of device has the potential to overtake current in vitro 
methods and become a physiologically relevant alternative to animal testing for the purpose 
of drug testing and toxicology.  
First, PDMS layers were constructed with microchannels using a soft lithography 
method. These layers come together to “sandwich” a membrane coated with collagen. Once 
sealed, the physiologically appropriate cells are grown to represent the nutrient/waste transfer 
of the placenta. Human Umbilical Vein Endothelial Cells (HUVEC) were grown on one side 
of the device and human trophoblast cells (BeWo) were grown on the other. The midsections 
of the channels are aligned so that the two cell groups are able to interact with one another 
across the membrane environment. Flow is administered through both channels at a rate of 6 
µl/hr.  
Utilizing the same basic design, a liver-on-a-chip was also investigated. . Human 
Umbilical Vein Endothelial Cells (HUVEC) were grown on one side of the device and either 
human liver carcinoma cells (HepG2). To better mimic the true in vivo microenvironment, 
the HepG2 cells are suspended in fibrin gel and flow is induced on only the endothelial 
channel at a constant flow rate of 6 µl/hr. Ethanol tests were performed on the liver-on-a-chip 
in which various concentrations were introduced into the medium, leading to a better 
representation of ethanol-induced liver toxicity. 
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CHAPTER I 
 INTRODUCTION 
 
1.1 Motivations 
Currently, we can classify current drug testing methods into two categories: in vivo 
and in vitro. In vivo (“within the living”) refers to drug testing that occurs within a biological 
lifeform. The most popular method of in vivo drug testing is testing through animal subjects. 
In vitro (“within the glass”) refers to drug testing that occurs on a non-biological platform. 
These platforms are constructed completely separate of the intended subject, but can contain 
biological components. An example of in vitro drug testing would be testing on a cell culture 
growing in a Petri dish.  
Both methods have their benefits, but they also contain many issues. For in vivo drug 
testing, it is clear that current methods are highly unethical, in that animals are harmed in the 
pursuit of studying the drugs intended and unintended effects. Animal models can also be an 
inaccurate representation of actual human physiological responses1. For example, let’s say 
that a drug was tested on a mouse to see if it was suitable for human use, and the drug was a 
success. This tells us that the drug was suitable for use on mice, but doesn’t tell us that the 
drug is suitable for humans.  That is not to say that using a similar, but not perfect animal 
model for the human can’t yield clues about the drugs effect and result in benefits, but it still 
requires us to make that leap of faith from animal models to human models. Additionally, 
animal models can also be extremely expensive, and require many hurdles to obtain. 
For in vitro drug testing, the biggest challenge is being able to replicate the 
complexity of the human anatomy. Animal models have experienced the success that they 
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have from being able to provide an environment that contain all the biological intricacies 
needed to show the drugs full range of effects. For in vitro drug testing, that environment is 
built from scratch. Additionally, in the pursuit of building this microenvironment, some sort 
of important physiological trait is either missed or sacrificed in favor of simplicity. Examples 
include having a two-dimensional model or having static flow conditions. 
The organ-on-a-chip field was created as a middle ground between these two 
methods, in which the in vivo microenvironment is recreated in an in vitro platform. The 
organ-on-a-chip is a 3D microfluidic device in which a constant media flow is induced over a 
cell culture model that is configured to represent the physiological functions of the organ. 
The media flow is typically delivered through a system of microchannels. These devices have 
the potential to replicate human organ functions, and can even be connected to create a 
“body-on-a-chip.” 
 
1.2 Background 
 Organ-on-a-chip devices have many benefits that make them an attractive alternative 
to other drug testing and toxicology devices. First of all, they take advantage of microfluidic 
phenomena. The large surface area to volume ratio leads to diffusive forces being dominant 
in the microchannels, as opposed to bulk forces2. The low Reynolds numbers that arise from 
these devices also gives the designer a smooth laminar flow that is easily manipulable and 
produce constant concentration gradients useful for long-term analysis3. 
 Another key feature of organ-on-a-chip devices that make them a desirable alternative 
drug testing method is that they use minimal products and materials to create and are 
relatively easy to manufacture. These qualities bring up an interesting feature for their future 
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implementation, which is the prospect of making these chips accessible worldwide, including 
third-world countries. 
 Additionally, this device presents a model that is physiologically similar to the body. 
In trying to compete with animal testing, it is important to understand that these organisms 
have had the time to evolve, perfecting themselves and optimizing their functional properties. 
Anything we can take from nature and implement in our design can prove to be an effective 
tool in designing the device. 
As stated in the previous section, the big challenge with in vitro devices is building up 
the biomimetic microsystem from scratch without eliminating any physiologically relevant 
traits. With limitless possibilities, researchers are given complete creative freedom to explore 
designs that they believe will optimize functionality. However, the choice of organ will be a 
determining factor in the design of the device. Chapter 2 will present a detailed review on 
organ-on-a-chip devices.   
 
1.3 References 
1. Fletcher, A. P., Drug Safety Tests and Subsequent Clinical Experience. J. R. Soc. 
Med. 1978, 71 (9), 693-696. 
2. Neuzil, P.; Giselbrecht, S.; Lange, K.; Huang, T. J.; Manz, A., Revisiting lab-on-a-
chip technology for drug discovery. Nat. Rev. Drug Discov. 2012, 11 (8), 620-632. 
3. Nguyen, N. T.; Shaegh, S. A. M.; Kashaninejad, N.; Phan, D. T., Design, fabrication 
and characterization of drug delivery systems based on lab-on-a-chip technology. Adv. Drug 
Deliv. Rev. 2013, 65 (11-12), 1403-1419. 
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CHAPTER 2 
 MICROFLUIDIC ORGAN-ON-A-CHIP TECHNOLOGY FOR ADVANCEMENT OF 
DRUG DEVELOPMENT AND TOXICOLOGY 
J.D. Caplin, N.G. Granados, M.R. James, R. Montazami, and N. Hashemi, "Microfluidic Organ-on-a-
Chip Technology for Advancement of Drug Development and Toxicology", Advanced Healthcare 
Materials, 4, 1426-1450 (2015) 
 
2.1 Abstract 
In recent years, the exploitation of phenomena surrounding microfluidics has seen an 
increase in popularity, as researchers have found a way to use their unique properties to 
create superior design alternatives.  One such application is representing the properties and 
functions of different organs on a microscale chip for the purpose of drug testing or tissue 
engineering.  With the introduction of “organ-on-a-chip” systems, researchers have proposed 
various methods on various organ-on-a-chip systems to mimic their in vivo counterparts.  In 
this review paper, a systematic approach was taken to review current technologies pertaining 
to organ-on-a-chip systems. Design processes with attention to the particular instruments, 
cells, and materials used were reviewed and presented.  
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2.2 Introduction 
Before a new drug is released in the market it must go through intensive testing; prior 
to approval for human testing, most drugs first need to be tested for safety through animal 
testing. The use of animals in such experiments is often expensive, time consuming, ethically 
controversial, and is often an inaccurate representation of actual human response [1]. Two-
dimensional cell culture models are also not the best solution because the cells do not 
respond the same way when their surrounding environment is drastically different from that 
of a human body [2]. Organ-on-a-chip technology provides a practical solution to many of the 
issues presented by both two-dimensional models and animal testing. An organ-on-a-chip is a 
cell culture model with microfluidic channels [3] configured such that it is capable of 
simulating the activities and physiological responses of an entire organ [4]. This type of 
device creates a uniquely accurate method for replicating the organ structure of human tissue 
and observing the biological responses, as opposed to predictions based on extrapolated data 
from animal testing. The chip is portable, requires little amounts of materials, creates a small 
footprint, and is cost effective, making its applications limitless [5].  With some more 
improvements and careful testing, this technology may be able to help drugs get into the 
market faster, increase the number of new drugs investigated, and possibly eliminate animal 
testing altogether. 
 Many ‘organ-on-a-chip’ devices have already been made [6]. For example, the Wyss 
Institute at Harvard have fabricated a ‘lung-on-a-chip’, which is mainly made of three 
microfluidic channels, with the center one holding a porous membrane on which alveolar 
epithelial and vascular cells are grown [7]. A breast-on-a-chip has also been developed to 
study tumor nanoparticles for identifying and treating tumor cells [8]. 
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The next step for this technology is to connect various organ-on-a-chip devices to one 
another to create a “body-on-a-chip.” This configuration could possibly allow researchers to 
investigate the effects of substances not only on the individual organs but to replicate the 
interactions between each component, providing a more comprehensive analysis which could 
ultimately revolutionize how drugs are developed. 
 
2.3 Microfluidic Organ Types and Functions 
2.3.1 Liver 
The approval of introducing new drugs to the market has proven to be a difficult barrier to 
overcome due to the risks associated with them. As the cost of bringing a new drug into the 
market keeps rising in the United States, there becomes a larger need to have high 
performance pre-clinical drug screenings using in vitro models. The liver has proven to be 
one of the most difficult organs for drug approval, due to the strong interactions it has with 
other organs, as well as its sensitivity to the metabolism of certain drugs [9].  This leads to a 
high percentage that are discontinued and removed from the market. Technologies to study 
microvascular structure and functions have remained largely unchanged since the late 1970’s. 
Improving the systems and technology used to test for toxicity is key to providing better 
predictions of toxicity and ensuring the safety and efficacy of new drugs well before they 
reach market [10]. There has been a considerable amount of research done in the area of 
toxicity testing on organs, with hopes to fabricate a simpler, efficient, effective, and accurate 
microfluidic system mimicking the functions of the liver. 
Cells used to represent the liver primarily consist of hepatocyte cells, due to their 
uncanny ability to mimic liver functions [11].  Research has taken advantage of this trait in 
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order to produce a working liver-on-a-chip design [12]. Toh et al. [13] created a system that can 
also address the cell culture chamber independently, so that different drugs concentrations 
can be simultaneously increased. The 3D microfluidic cell culture system, dubbed the “3D 
HepaTox Chip,” is designed to support 8 parallel channels containing separate cell cultures, 
with a linear concentration generator to provide different levels of drug concentration to each 
channel. An array of micropillars (30 µm x 50 µm) separate the cell culture channel into 
three compartments consisting of a 200 µm wide central culture with two side compartments.  
The central culture had the purpose of keeping a constant cell suspension, while the side 
compartments introduced flow from the output of the concentration generator. To assess the 
functionality of the cell culture, albumin production and various metabolic activities were 
measured. Results showed that this microfluidic model was equally capable of the functional 
maintenance of the hepatocytes as a multi-well plate model, if not more so.  The 
hepatotoxicity testing was performed using five model drugs: acetaminophen (20mM), 
diclofenac (1000µM), quinidine (1000µM), rifampin (2000µM) and ketoconazole (420µM). 
Results showed that the cells were more sensitive to the drug-mediated hepatotoxicity than 
the multi-well plate cultures. The toxicity data also showed a positive correlation with 
comparable in vivo toxicity data.  
While some researchers focus on using 3D microfluidic devices for toxicity testing, 
others have focused on functionality.  Nakao et al. [14] developed a microfluidic cell culture 
device that mimics the microscopic structure of the hepatic cords. Due to the decline in liver 
specific functions caused by freshly isolated hepatocytes rapidly losing their membrane 
polarity, a new technique for maintaining the cells was proposed, in which hepatic activity 
was prolonged by suctioning the cells into the cord-like compartment of the device, creating 
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a “collagen sandwich culture”. The design is such that the tip of this compartment has an 
asymmetrical tip that can house two cells side-by-side. Current liver tissue cultures do not a 
have separate compartment to collect secreted bile and are accumulated in the cultured cells. 
However, in vivo, the bile is excreted into the bile canaliculi and is then discharged into bile 
ducts. The area of culture was formed by aligning two lines of hepatocyte cells in a similar 
way to the hepatic cords. The aligned hepatocytes were able to self-organize themselves and 
form bile canaliculi along the hepatic cord-like structure. The device has a medium flow 
channel that is 100µm wide and 30µm high, a cell loading channel that is 200µm wide and 
30µm high, a cell culture area that is 37µm wide and 30µm high and an endothelial-like 
barrier. Additionally, there are 30µm long narrow slits with 10µm intervals that allow the 
nutrition to go into the cell culture area. The fluorescent substrates accumulated in the cells 
were aligned and formed a bile canaliculi with tight junctions. This bile canaliculi showed 
the ability to utilize nutrients in the culture medium stream. Additionally, using the MRP2 
and CD147 marker proteins, the transportation properties of the system were tested, and the 
markers were found to be distributed in a similar fashion as they would in an in vivo 
counterparts. 
Incorporation of biosensors has also been studied as a means to create improved 
analysis of a system, in addition to the development of the microfluidic platform. As part of 
the construction done by Schober et al. [15], AlGaN/GaN nanosensors were integrated into 
their microdevices, and were used for optical monitoring of the cells. The design consists of a 
base and top module used for the purpose of carrying the cell culturing substrate; within this 
contains a microfluidic pumping system used for circulation and perfusion.  The cultivated 
cells are contained in a polymer scaffold system, called “MatriGrid.” The hepatoma cell line, 
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HepG2, demonstrated the biological application of the microreactor. Analysis was done for 
2D cell culture, 3D culture without perfusion, and 3D culture with perfusion. Tests for 
viability were completed and analyzed for the cells cultured in the 2D and 3D systems over a 
course of 19 days. All three cultures showed a similar general relationship between the G1,0, 
D, and G2,m phases, with the 2D culture displaying a higher proliferation rate than what is 
typically seen in vivo.  The notable difference came from monitoring the albumin secretion of 
the cultures. Albumin secretion was used as a metabolic marker to observe the similarities 
between the cultures used during the experiment and the in vivo counterpart.  Results showed 
that only the 3D culture without perfusion strayed from predicted results, showing a notable 
increase in production over time.  Additionally, the system with and without HepG2 cells 
went through pH testing.  The results showed a steading increase in pH for the system with 
HepG2 cells, and a relatively unchanged pH for the system without.  This is due to the 
conversion of glucose to lactate that occurs in vivo as well. These results showed a strong 
signal with little noise,showing reliability that can be applied for long-term monitoring of 
cells. Their perfused bioreactor system mimics some of the features that are found in vivo as 
well. 
Lee et al. [16] designed a microfluidic device that contained polyethyleneglycol (PEG) 
pillars within a weaving channel, with each pillar containing rat liver microsomes enclosed 
within a 3D hydrogel matrix.  The pillars took up around 35% of the space within the channel 
and were roughly spaced 100µm from each other. Gravity induced flow was able to mimic 
the metabolism reaction and the transport system of the liver. The concentrations of seven 
different substrates were used to test the P450 reaction in a microsome solution within a 
standard well plate system, ranging from 2µM to 80µM. Two trials were conducted: one in 
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which the microsomes were in the solution phase by themselves and another in which the 
microsomes were enclosed within the 3D matrix.  Data was extrapolated and a mathematical 
model of the system based on Michaelis-Menten kinetics was produced, showing a high level 
of agreement between the two. The chip was then analyzed and a model was created.  This 
model also showed a high level of agreement. However, ideal assumptions were created to 
simplify the model, including: no variation in the z-axis, completely effective diffusive 
properties within the channels, a completely homogeneous environment (a single diffusion 
coefficient), and a uniform reaction space within the channel. Certain steps still need to be 
taken to improve the model, like improving the diffusive properties and convective flow rate 
of the device, but the success of the model shows that the metabolic properties within a 
microfluidic liver model can be mapped and understood to create an experimental equivalent 
for use in liver-on-a-chip applications.  
While the use of a single cell culture has shown to yield successful results, using 
multiple cells in a liver-on-a-chip model has the potential for even more realistic in vitro 
results due to the livers true complex nature being composed of multiple cells in interaction 
with each other. This line of research has produced notable results as well [17].  Schütte et al. 
[18] used this approach, in addition to developing a microfluidic test system for liver toxicity. 
This system is an organ-like liver 3D co-culture of hepatocytes and endothelial cells. The 
chip allows for the assembly of primary human hepatocytes and endothelial cells in a 
sinusoidal-like manner with the use of dielectrophoresis (DEP). The system was integrated 
with microfluidic channels that allowed for continuous perfusion of the culture medium and 
compound testing. The features within the channel structure are comprised of electrodes at 
the outer chamber walls with a variation of the channel cross-section in between. Micro 
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pillars were attached to the front and back ends of the gaps to represent flow barriers, which 
reduced the flow velocity and shear forces. The device was connected to a pump system for 
fluid control with AC voltages of up to 300 Vpp. Each design had a gap region 100μm high, 
100μm wide, and 1,500μm long, as well as a 33º angle of inclination on the bottom channel 
so that particles traveling along the bottom can still be lifted into the gaps by 
dielectrophoretic force (Fig. 1a). The device only trapped the healthy living cells, thereby 
resolving a problem of the past. Once the electric field was turned off, the cells showed a 
more even distribution, with the hepatocyte cells in the center and the endothelial cells 
outside of them (Fig. 1b).  This distribution was sufficient enough to not be affected by the 
flow. 
 
Fig. 1. Cross section of the microchannel displaying the general layout.  Two electrodes are 
positioned at each wall of the channel, a) providing a dielectrophoretic force to the 
hepatocytes and the endothelial cells traveling along with the flow once voltage is applied to 
the system, with the design of the device such that the particles are maintained in the center.  
b) Once the voltage is shut off, the particles are arranged such that the endothelial cells are 
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positioned outside of the hepatocytes, while still being somewhat maintained in the center of 
the channel [18]. 
 
Another multi-cell design was created by Wagner et al. [19], who designed a multi-
organ chip (MOC) platform that combined a microfluidic channel system with multiple 
separate tissue culture compartments. Liver micro tissues (HepaRG and HHSteC), as well as 
skin biopsies, were combined and had successful long-term performance. The device 
contained microchannels and micropumps, as well as culture compartments for Transwell® 
inserts. The system allowed crosstalk between the two tissues, and was observed for 14 days 
while exposed to fluid flow. Consistent disk-shaped liver cells were formed during 2 days of 
having been cultured on the chip. The microchip device was able to culture two cell types 
while directly exposed to fluid flow, as well as maintain a metabolic steady state. It is able to 
culture and maintain cells over longer periods of time with the Transwell® inserts as the 
system showed it could be maintained for 28 days. 
 Additionally, multiple toxins can be used as well to increase the scope of the 
experiment.  Shintu et al. [20] developed a microfluidic system with H NMR-based 
metabolomic foot printing. They used a small-molecule screening approach to characterize 
the toxicity in several compounds: ammonia (NH3), dimethylsulfoxide (DMSO), and 
acetaminophen (APAP). Hepatocellular carcinoma cells (HepG2/C3A) were used to model 
the liver, Madin-Darby canine kidney (MDCK) tubular epithelial cells to model the kidney, 
and a combination of both (HepG2/C3A-MDCK) as cell co-cultures. When the biochips are 
perfused, the supply of nutrients is restored, the cells proliferate, and a higher glucose and 
glutamine consumption is seen. HepG2/C3A is correlated with higher glucose concentrations 
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and lower lactate and alanine concentrations when compared to the MDCK kidney. 
Additionally, the co-culture showed unique metabolite concentrations not expressed in any of 
the single cultures.  This information was used to control these differences to ensure that they 
have the same “starting point” with relation to their reaction with the compounds. A data-
scaling method known as “SMART-scale analysis” was used to account for these differences.  
Using this method, the relative increase and decrease of metabolic markers was analyzed. 
These fluctuations, both alone and in combination with one another, can create results in 
various biological processes, including toxicity production.  An “integrated knowledge 
network” was created to map out these biological processes and their implications.  From 
this, the actions from the metabolic markers can be observed for toxicity screening purposes.  
Experimental results were conducted and the metabolic responses were observed and 
compared alongside the theoretical data.  The results showed a high degree of compatibility 
for all three compounds. 
Integrating tissue slices is another technique used by researchers to create an in vitro 
co-culture model [21].   Van Midwoud et al. [22] investigated whether intestinal tissue slices 
could also be cultured in a micro biochip with liver slices and also to see if their metabolic 
activity in incubation is better than in the well plate system. The intestine, as well as the liver, 
is important for the metabolism of xenobiotics. The liver and intestinal slices were obtained 
from male Wistar rats. They exposed the substrates to several mediums: 7-ethoxycoumarin 
(7-EC), 7-hydroxycoumarin (7-HC) and lidocaine (Li), to see if their metabolic rates in the 
biochip were similar. The slices were also exposed to a primary bile acid, chenodeoxycholic 
acid (CDCA), to see the interplay between the two organs. One slice of liver and one slice of 
intestine were placed into a compartment culture perfusion system with a continuous flow of 
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the mentioned mediums. The microdevice itself had 10 layers of polydimethylsiloxane 
(PDMS), which each had a thickness of 250µm and along with 6 microchambers. The device 
had a medium top/bottom inlet channel that was 500µm x 100µm, and a polycarbonate filter 
that had 8µm size pores and 10µm in thickness integrated at the entrance of the tissue 
chamber. The filter was 4mm x 2mm and held 25µL. It was found that it is possible to 
successfully maintain intestinal slices in the same biochip with viability and functionality for 
at least 3 hours. With this system they were able to easily control the flow of the medium and 
transfer it from one organ to another. It was also possible to link one microchamber to 
another for the use of perfusion and metabolic activity. They were able to integrate the liver 
and intestine, and it could potentially work for lung, kidney, and colon slices. 
Just like van Midwoud et al., Bricks et al. [23] developed a model to mimic the 
interactions between the intestine and liver. However, instead of using actual slices of the 
organs, they used the human carcinogenic epithelial cell line Caco-2 TC7, which is the clone 
of Caco-2 cells, for the intestine, and hepatocarcinoma HepG2/C3A cells for the liver. A new 
microfluidic device called the Integrated Insert in a Dynamic Microfluidic Platform, or 
IIDMP, was used to evaluate the organ-organ interactions of the liver and intestine. This 
design consisted of 3 perfusion units, each unit containing two wells used as reservoirs, one 
cell culture insert, and one microfluidic chip that was made of PDMS. The insert was 
contained within the first well, with circulation traveling through the bottom of the first well 
into the second well, by means of a microfluidic chip bridging the two wells.  A pump was 
used to bring flow from the second well back into the first well, thereby completing the 
cycle. The Caco-2 TC7 cells were cultured in the insert, while the HepG2/C3A cells were 
cultured in the microfluidic chip.  Both cells were individually tested for integrity and 
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functionality before integration into the system.  Confluence of Caco-2 TC7 cells were found 
using transepithelial electrical resistance (TEER) measurements and permeability properties 
were found by monitoring Lucifer yellow transportation. Results showed high levels of both 
after sufficient time within static culture, suggesting that the system gained tight junction 
properties, which is in agreement with expected results.  Dynamic conditions proved to 
produce similar results.  HepG2/C3A cells were cultivated and the functional properties were 
tested in both dynamic and static conditions.  Dynamic conditions were tested with and 
without the influence of Caco-2 TC7 cells in the system.  Albumin production was reported 
to be non-existent in the static culture, while producing higher values with the influence of 
Caco-2 TC7 cells compared to the system without them, despite the fact that the Caco-2 TC7 
cells showed no production of albumin themselves.  Bricks et al. proposed that this was due 
to a stimulating effect that the Caco-2 TC7 cells have on the HepG2/C3A cells.  The 
xenobiotic metabolism was tested using the EROD test.  The enzyme CYP1A was chosen for 
monitoring.  Results showed low levels of activity when compared to primary hepatocytes, 
with dynamic trials showing no metabolism after 24 hours and static trials showing no 
activity at all after 24 hours.  The co-culture of Caco-2 TC7 cells and HepG2/C3A cells were 
then tested by monitoring the CYP1A activity when the drug phenacetin was introduced to 
the system.  Both static (Petri) and dynamic (IIDMP) were evaluated.  The resulting APAP 
production was observed to be higher in the dynamic culture, despite the fact that the 
hydrophobic properties of phenacetin may have led some of it to be absorbed into the PDMS 
components of the IIDMP.  When dynamic conditions with and without Caco-2 TC7 were 
tested, the system with Caco-2 TC7 once again produced greater amounts of production.  
This experiment reaffirms the hypothesis that integration of tissues from multiple organs 
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creates a more realistic in vitro model due to both the simple connections and the underlying 
influences they have on each other. 
 
2.3.2 Lung 
In response to the lack of experimental model systems available that can accurately replicate 
human lung response and function, many are currently researching and developing new 
technologies. The microdevice, lung-on-a-chip, recapitulates the physiological and 
mechanical microenvironment of a living lung. This technology allows for the study of 
complex physiology of the human lung. With the aid of organ-on-a-chip technology, new 
drug therapies can be developed, respiratory assist devices can be utilized, and pulmonary 
diseases can be characterized [24]. 
In early work by Huh et al. [25], a microdevice was developed which allowed for the 
analysis of the effects of liquid plug flows on human small airway epithelial cells (SAEC). 
The device consisted of two PDMS layers containing a microfluidic channel separated by a 
nanoporous membrane, modeled after the human airway epithelium.  Additional inlets and 
channels were created to connect a liquid plug flow generator.  Liquid plug flows were 
created using a device that would switch the air-liquid interface within the chip, as shown in 
Fig. 2. Through this device, the effects of an air intake model (useful for representing a 
healthy lung), fluid intake model (useful for representing the developing lung of a fetus), and 
a variable length two-phase plug flow model (useful for representing respiratory diseases 
such as pulmonary edema) on the cells can be monitored as the system operates.  Small 
airway epithelial cells were first cultured in a culture media on the membrane until a 
confluent layer was formed, then exposed to air in the culture chamber.  Using a laser 
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vibrometer, the magnitude of the pressure waves from the liquid plug flows was measured.  
The Weibel model was used as a reference for the size and speed of the plug flow.  At a rate 
of 1 plug per minute, the results showed that only 24% of the cells survived after 10 minutes, 
with most damage occurring downstream where the plug erupted.  This result shows the 
capabilities of lung-on-a-chip devices for representing pulmonary diseases in a microfluidic 
platform. 
 
Fig. 2. Process of creating the liquid plug for the microsystem.  The process begins with A) 
air being produced in the upper inlet and liquid being produced in the lower inlet. Liquid is 
flowing from the lower inlet into the waste stream, so that the only fluid within the culture 
chamber is air.  B) The plug is started once the upper inlet is blocked, bringing liquid into 
the culture chamber. C) The plug is complete once the upper inlet is reopened and the liquid 
from the lower inlet is once again only flowing into the waste stream.  D) A complete picture 
of the plug system and the microfluidic chip can be seen, with the actual chip being 
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highlighted in yellow.  The plug will slowly dissipate as it travels through the chip until it 
ruptures, E) releasing pressure waves in the system that can be monitored [25]. 
 
In a similar experiment designed to study the damage of lung cells by recreating 
liquid plug flow, a microfluidic device was developed by Tavana et al. to monitor the 
induction of pulmonary pressure on the culture system [26]. While the device shows a similar 
design to the previous design by Huh et al. for the integration of the liquid plug and the 
culture chamber, this project is designed to look at the role that surfactants play in the 
damage of lung cells.  Deficiencies of pulmonary surfactants occur from the destabilization 
of liquid lining of small airways causing osculating liquid plugs. In vivo, this is prevented by 
the secretion of a liquid surfactant from the alveolar epithelial cells. Human alveolar 
epithelial cells were used for the model, and cultured in F-12K medium. An air tank was used 
to supply air and a syringe pump was used to supply liquid. Size and duration of the plug 
flow was determined using a pressure transducer controlled by a DAQ board. During the 
experiment, the microchip was placed on a glass slide and observed on a microscope. Cells 
were stained with CellMask Deep Red plasma membrane stain to monitor the effects of the 
liquid plugs. The cells were imaged using an inverted florescence microscope.  A surfactant-
free trial was run on the device, showing extensive injury to the lung cells. The surfactant, 
Survanta, was then introduced at 1 mg per ml of buffer for the next trial. Results showed a 
major decrease in the percentage of cell injuries in the system. For comparison, the 
surfactant-free trial showed a cell viability of 63% after three plugs, whereas the surfactant 
trial showed a cell viability of 81% after five plugs.  This in vitro pulmonary airway platform 
can be used to study cellular and sub-cellular effects in airway reopening.  
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Built on the work of his previous design, Huh et al. [7] designed and fabricated a 
biomimetic microsystem in 2010 to not only mimic the cellular and diffusive properties of 
the lung, but also the macroscopic behavior, such as the expansion and compression of the 
system to mimic inhaling and exhaling. The microfluidic system consisted of two 
microchannels that were separated by a membrane of polydimethysilxane (PDMS), as 
opposed to a membrane of polyester in the earlier design. This lung-on-a-chip system is 
capable of mimicking the human lung's response to bacteria and inflammatory cytokines. The 
membrane was coated with ECM and human alveolar epithelial cells (NCI H441), and 
human pulmonary microvascular endothelial cells were cultured on the opposite side of the 
membrane (Fig. 3A). Two hollow mirochannels on either side of the flexible membrane 
acted as vacuum chambers to simulate breathing movements (Fig. 3C, D, E). This design 
took advantage of the flexible PDMS membrane to better recreate physiological breathing 
(Fig. 3B). Through the study they also found that due to the mechanical strain of air being 
pulled in and out of the lung, the epithelial and endothelial uptake of nano particulates were 
enhanced and stimulated their transport into the underlying microvascular channel. To test 
their device, bacteria and inflammatory cytokines were introduced into the air, and human 
bloodborne immune cells were introduced into the blood-like fluid. It was observed that the 
lung-on-a-chip can mimic the innate cellular response to pulmonary infection of bacterial 
origin. However there are still differences between in vivo and the device, such as changes in 
air pressure and flow, cellular composition, and barrier thickness, that still need to be 
accounted for before it becomes a reliable alternative to animal testing.  
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Fig. 3. Design layout for lung-on-a-chip, showing A) a cross-sectional view of the device. 
Human alveolar epithelial cells are cultivated on the top of the membrane, while human 
pulmonary microvascular endothelial cells are cultivated on the bottom of the membrane. B) 
A view of the human lungs, showing the stretch and the resulting distribution of the air intake 
during the inhalation portion of the breathing cycle. C) The device consists of two PDMS 
layers with a porous membrane separating them. D) Once the layers are sealed, an etchant 
flows through the vacuum chambers. E) The finished design of the chip, with a quarter for 
scale [7]. 
 
The work done to mimic pulmonary edema in a human disease model-on-a-chip was 
expanded by Huh et al. [27] in 2012. The devices used in the study were slightly modified 
from previous work [7]. Once again PDMS was used as the top and bottom layers of the chip. 
21 
 
 
The side chambers were created by etching the membrane layers in the side microchannels 
with tetrabutylammonium fluoride and N-methylpyrrolidinone, mixed at a ratio of 1:3. The 
solution was introduced into the side microchannels through inlet reservoirs by either 
hydrostatic pressure or vacuum suction. Etching took place until the thickness of the PDMS 
walls between the side chambers from the central culture chambers became thinner than 
30µm. Afterwards, the side chambers were washed with NMP to remove any PDMS etchant 
that remained.  After the alveolar epithelial cells were attached to the upper alveolar channel, 
culture media flowed through the device at 50µl/hour. Cells were grown for 5 days; on day 5 
the culture medium was aspirated from the upper channel and a 50:50 mixture of epithelial 
and endothelial medium was introduced into the lower channel. This fed the alveolar 
epithelial cells on their basolateral side. For 15 days, epithelial cells were grown at an air-
liquid interface. Just as in the previous device [7], the upper alveolar channel was filled with 
air and the lower microvascular channel was filled with liquid. Additionally, a vacuum was 
connected to the system to mimic breathing motion as a functioning human lung. It was 
shown that with the addition of cyclic mechanical strain to IL_2, leakage increased 
dramatically. The drug DSK2193874 was tested and shown that it could inhibit leakage. This 
demonstrates an additional step towards mimicking lung functions, and brings research one 
step closer to successfully predicting the activity of a new drug for cases involving 
pulmonary edema. The goal of having the ability to rapidly screen many drugs and 
conditions could one day become a reality once models can be connected to many other 
organ-on-a-chip models. This could bring about a more accurate representation of how 
pharmaceuticals affect all areas of the body. 
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Other mechanical properties were explored by the microsystem created by Douville et 
al. [28], who observed the effects of both solid and fluid mechanical stress on alveolar 
epithelial cells with a ventilator-induced lung injury (VILI). The device consisted of three 
major components: the alveolar chamber, PDMS membrane, and actuation channel. Human 
alveolar basal epithelial (A549, AEC) cells were culture in this model. The main contributor 
to solid mechanical stress for VILI is the cyclic stretching of the cells, while the main 
contributor to fluid mechanical stress is an air-fluid meniscus. Advancing versus receding 
menisci were observed for their stress impact as well (Fig. 4.), with the confirmation that a 
receding meniscus causes more harm to cells than an advancing one. A finite element 
analysis (FEA) model was used to estimate the solid mechanical stress and the resulting 
model was proposed as a means to estimate the stress profile by measuring the maximum 
deformation of the system.  Results showed a viability of 16.8% in the A549 cells and 32.5% 
in the AEC cells when exposed to both solid and liquid mechanical stress. This study 
prompts further research on understanding techniques to eliminate hazardous stresses in 
clinical settings.  
 
 
23 
 
 
 
Fig. 4. Monitoring and computational fluid dynamic (CFD) analysis on the mechanical 
stresses of an advancing meniscus fluid plug versus a receding meniscus fluid plug. A) The 
streamlines of both menisci are displayed, with U = 1cm/s.  B) The half-meniscus profile was 
calculated and graphed.  The results show a smooth profile for the advancing meniscus (red), 
while the receding meniscus (black) contains abnormalities when focused on the edge of 
curvature (exaggerated display is boxed) that will increase the stress applied on the cell 
layer [28]. 
 
While these designs have improved the functionality of an in vitro lung design, a 
major problem with these designs is their poor permeability when compared to an actual 
working lung.  This issue was addressed by Kniazeva et al. [29], who created a microfluidic 
design to maximize gas transfer, with the goal of working towards creating an artificial lung 
or a lung assistant device. The design consisted of a small branched network of channels 
representing the microvascular system, with an ultrathin membrane separating the 
microvascular network from the channel representing oxygen flow. This design is repeated to 
create a multi-layer design with alternating levels of microvascular channels and oxygen 
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channels. The ultrathin gas exchange membrane is used to maximize gas transfer efficiency 
while minimizing membrane-blood contact area, which is one of the main challenges in 
artificial lung technology. The network is designed to minimize blood damage, thrombosis, 
and inflammatory responses. The microvascular network also provides controlled wall shear 
stress and uniform blood flow. The device addresses many limitations seen in lung assist 
devices such as the Extra Corporeal Membrane Oxygenator (ECMO). Current ECMO 
devices have surface area to volume ratios that are 10 times less than the natural lining of a 
human lung.  Additionally, the gas diffusion distance in the ECMO is 10-30µm greater than 
the 1µm observed in the natural lining. Leaks of proteins, phospholipids, and lipoproteins 
often occur, which cause device failure. ECMOs also use non-physiological blood flow 
pathways that can be unpredictable and uncontrollable. The membrane used in this device is 
thinner than the membranes used in ECMO devices, thus less surface area is required for 
equivalent oxygen transfer and the membrane is more gas permeable. Two different methods 
were used to test the device. The first test characterized the permeance of the PDMS 
membrane in a static medium. The second test analyzed oxygen transfer through the 
membrane. It was found through experiments that as the membranes became thinner, the 
permeance increases. The relationship was modeled with the equation:  
K=Q2/SA·ΔP       (1) 
 where K is the permeance, Q2  is the  actual oxygen flow rate, SA is the surface area of 
oxygen transfer (was the same for each device), and ΔP is the transmembrane pressure. 
Following Eqn. 1., it was found that K stayed relatively constant at a given membrane 
thickness. Therefore, as the transmembrane pressure doubled, the flow rate also doubled. The 
bilayer subunits that make up this device are easily reproduced and can be connected in 
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different configurations. Membrane thickness can also be controlled and optimized. It was 
found that by using thinner sheets to create channels, overall oxygen transfer was increased. 
This device will be useful in artificial lung and lung assistant device applications that require 
high transfer rates of oxygen. 
Many lung assist devices today are limited to care unit settings because they are not 
implantable or portable.  From this, lung assist microdevices that utilize vascular networks 
are being designed, with the hopes that they can be implanted in the patient [30].  Sreenivasan 
et al. [31] developed a lung assist device that is designed to achieve physiologic flow through 
utilizing microfluidic vascular networks, which may allow this device to be implanted if it is 
impermeable to fluid.  Sreenivasan et al. aimed to improve their previous 8µm silicon 
membrane by designing the gas exchange membrane to be more permeable. They designed 
and developed a free-standing membranes (FSM) and composite membranes (CM) by means 
of initiated Chemical Vapor Deposition (iCVD). A control membrane of 8µm thick spun cast 
silicone was used to compare the two designs. Both devices were also tested for bond 
integrity. Sreenivasan et al. chose to work with p(nBA) and p(tBA) based chemicals for  free-
standing membranes due to their ability to withstand bonding. The p(AA) was spun at 4000 
rpm for 40s then baked at 150 °C for 2 minutes to create a sacrificial layer. The p(AA) would 
then dissolve away, leaving the FSMs. The FSMs successfully remained intact during 
handling.  The FSM with a thickness of 5µm expressed a CO2 permeance 1.3 times higher 
than the control membrane.  An alternative to ultrathin FSMs are composite membranes. 
CMs are composed of a highly permeable porous structure coated with a skin of a secondary 
polymer. These 0.1µm commercially available membranes provide mechanical stability to 
the device and minimize the chances of membrane rupture. The top skin layer allows gas 
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transfer, while acting as a separation for liquid and gas. The CMs expressed CO2 and O2 
permeance of 50-300 times the control membrane. These CMs are on the right track to 
achieving the permeable membrane needed for portable lung assist device. Defect-free 
thinner membranes (20-500 nm) are currently under development. 
Microfluidics can also be applied for the characterization of cellular responses, such 
as the correlation of the expression of Glucose Regulated Protein-78 (GRP78) and the 
resistance to anticancer drug VP-16 in lung cancer squamous carcinoma cell line SK-MES-1, 
researched by Siyan et al.[32]. Chemotherapy is hindered by cells that are resistant to the 
treatment. Little is known about the function of GRP78 because many in vitro detection 
methods are tedious, use large quantities of reagents, and require troublesome liquid handling 
procedures. The microfluidic chip contains an upstream concentration gradient generator and 
a downstream cell culture module. Their design was based on previous work by Jeon et al 
[33]. More will be discussed about cancer modeling on a chip in a later section. 
A chip modeling the nasal passage, specifically the nasal epithelium, was designed by 
Wang et al. [34]. This is useful because the nasal epithelial can be one of the first cells 
exposed to environmental agents.  Human nasal cilia beating behaviors, a defense mechanism 
of the airway, were investigated by testing its reaction to gaseous formaldehyde. A 
microfluidic system was used because it allows for good control and offers highly sensitive 
molecule detection. The microchip was made from molded PDMS and contained a square 
chamber (10mm x 10mm x 30µm, width x length x depth) separating two straight channels. 
Human nasal epithelial step progenitor cells (hNESPCs) were cultured on the device’s 
membrane located at the square chamber. A bottle containing formaldehyde was connected 
to one of the straight channels (inlet), while a withdrawing syringe pump system was 
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connected to the outlet. Cilia beating frequency (CBF) was monitored at different gaseous 
formaldehyde concentrations (0.5 mg m-3, 1.0 mg m-3, 3.0 mg m-3). While the 0.5 mg m-3 
trial remained relatively stagnant, the 1.0 mg m-3 trial showed a CBF that increased 
immediately and continued to increase throughout the course of the trial. When exposed to 
high concentrations of 3.0 mg m-3 formaldehyde, it was observed that CBF slightly decreased 
instead of increasing. This may be due to the toxic effects on the epithelial cells.  The 
resulting experiment was shown to be a successful model of the nasal epithelium and has the 
potential to be used in clinical applications as well.  
 
2.3.3 Intestine 
Most oral drugs and nutritive substances are effective only after they are absorbed into the 
blood circulation through the intestine [35]. The evaluation of the intestinal absorption is 
important in the pharmaceutical and nutritional fields. The development of in vitro cell-based 
models for the intestine that mimic the mechanical, structural, and pathophysiological 
properties of drugs and nutrients is needed.  
Organ-organ and drug-drug interactions are very important when working with drugs. 
How one cell reacts to another based on the effects of a certain drug can either allow a new 
drug onto the market or not. For example, van Midwoud et al. [22] was one of the first to 
connect a liver and intestinal organ to allow for inter-organ interactions with applications 
towards toxicity testing. Bricks et al. [23] did a similar project using liver and intestinal cells 
as well.  
A similar project that combined the liver with the intestine was done by Mahler et al. 
[36], who used a microscale microfluidic cell culture analog (µCCA) of the gastrointestinal 
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tract (GI), as well as the liver, to predict drug toxicity. APAP was used as a model drug to 
test the group’s hypothesis that the passage and metabolism of APAP in the intestinal 
epithelial monolayer, followed by absorption into liver, would lead to low concentrations of 
glutathione and low viability of cells. Their goal was to create a complete in vitro human 
gastrointestinal tract model that is inexpensive, quick, and accurate to that of the human 
organs’ response to orally ingested drugs, chemicals, and the resulting cell-cell interactions. 
In vivo, the lining of the small intestine membrane is composed of enterocyte and goblet 
cells. The enterocytes make up most of the population and control the transport of molecules, 
while the goblet cells secrete a mucus designed to protect the lining of the membrane. The 
functions of these two cell types must be taken into consideration in order to produce a 
working drug absorption model in vitro. The cell line Hepg2/C3A was used to represent the 
liver, while a co-culture of Caco-2 and HT29-MTX cell lines at a 3:1 ratio was used to 
represent the intestinal cells. The design consisted of a GI tract µCCA that led into a systemic 
µCCA that represented the liver, fat, kidney, and bone marrow.  A peristaltic pump was used 
to control circulation and a reservoir compartment was connected to this system to control 
any sort of excessive pooling.  It is important to note that only the GI tract and the liver 
pathways contained cells.  The fat, kidney, and bone marrow chambers were only used to 
represent the distribution of fluid. The membrane was made of a polycarbonate with 0.4 µm 
pores and a Type I collagen coating. The cells were stained with calcein and 
monocholorobimane to visualize the monolayer integrity. Trials in this system were run for a 
course of 24 hours. The results showed an inverse relationship between the concentration of 
APAP and the concentration of glutathione and cell viability. The products of APAP, APAP-
GLUC and APAP-SULF, were monitored throughout the trials as well.  Results showed that 
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APAP-GLUC was produced fairly quick at the beginning of the experiment, but remained 
constant after the sixth hour.  APAP-SULF showed concentrations that were ten times higher 
than that of APAP-GLUC for the first six hours, with a steady increase throughout the entire 
trial. This experiment showed GI tract-liver characteristics that showed they were able to 
digest APAP, with close observation to their viability and the products formed in the 
reaction.  While they still are not able to produce the same levels of digestion as an in vivo 
equivalent, these results are fairly agreeable with in vivo results. 
There have been many studies on the microfluidic in vitro design of the 
gastrointestinal tract and stomach for toxicity testing, drug testing, and mimicking key 
functional and structural parts. The use of hydrogels as a platform for cultivated cells in a GI 
tract design has been explored as well [37]. Sung et al. [38] developed a 3D collagen scaffold 
that mimicked the human intestinal villi. The technique used to create the hydrogel involved 
laser ablation to carve out holds on a plastic mold.  This plastic mold was used to create a 
reverse-mold out of PDMS.  Then, the reverse-mold PDMS was used to create a second mold 
that was made of calcium alginate.  The hydrogel was built off of this mold, which eventually 
dissolved. The molds and structures were built with dimensions mimicking that of intestinal 
villi. Caco-2 cells were cultivated on the hydrogel villi, resulting in an in vitro system with 
close structural similarities to human jejunal villi. Cells could either be encapsulated in the 
hydrogel or seeded into the structure to be cultured. Collagen and polyethylene glycol 
diacrylate (PEG-DA) were used as the two types of hydrogels. Their system is simple and 
does not require expensive or complex equipment, which is a requirement for most 
microfabrication methods. While a microfluidic analysis was not done on the hydrogels, 
observation of the culture within the hydrogels revealed a successful layer of Caco-2 cells. 
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With an analysis of flow from both sides of the device, a study of the dynamics of drug 
absorption in the GI tract can one day be done.  
Although some models are used for the testing of toxins or drugs, a model for bacteria 
is rarely seen in microfluidic models. Kim et al. [39] created a model that had bacteria grown 
and added to healthy intestinal cells to see how they reacted. Instead of modeling the 
gastrointestinal tract for its functions and mechanical properties like with previous 
researchers, a GI tract infection was chosen as the focus. The system mimics the sequence of 
events in a gastrointestinal (GI) tract infection, specifically the invasion of bacteria on the 
intestinal cells. In the human body, a healthy GI tract can be defined by the balance of the 
interactions between the commensal bacteria and the intestinal epithelial cells.  Pathogens 
often out-compete the bacteria and attach to the epithelial cells and begin an infection even 
though there are more commensal bacteria than pathogens. The molecular signals that are 
given off by the GI tract allow the commensal bacteria to prevent pathogen colonization or 
infection. In the model, this relationship is studied with a microfluidic device contained a co-
culture of epithelial cells and bacteria. The group used E. coli as the prototypic commensal 
bacterium and HeLa S3 cells as the model for the intestinal epithelial cells. The pathogen 
used was E. coli O157:H7, a harmful strain of E. coli. The device consisted of a large 
chamber used to culture the epithelial cells and two “islands” used to culture bacteria. The 
two islands were located 1000 µm apart and were lowered and raised on a 100 µm thick 
PDMS wall. The cells grew a confluent layer and the bacteria produced a biofilm. Then the 
pathogen was introduced to the biofilm, followed by exposure of the epithelial cells. 
Resulting data showed a specific signal, indole, as having a huge effect on the resulting HeLa 
cell viability (which is directly correlated with the level of infection from the pathogen).  
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Commensal bacteria that lacked this signal produced half the viability than when it was 
present.  A trial in which 500µM of indole was directly introduced to the pathogens also 
showed an increase in HeLa viability, but not to the extent of a natural signal.. The group 
states that future work in determining biofilm thickness and the extent of the pathogen 
colonization are the next steps needed to better reproducing their model.  
In 2012, the group of researchers from Kim et al. [40] developed a “human-gut-on-a-
chip” that utilizes dynamic motions on the microdevice to better mimic the structure and 
function of the living intestine. This dynamic environment is created by the flow of the fluid 
through the channels, as well as the application of cyclic strain by use of vacuums within side 
chambers to mimic peristaltic motion. The design is similar to that of Huh et al. “lung-on-a-
chip” design [7], in which two side chambers are utilized as vacuums to control the motions 
that the organ experiences in vivo (Fig. 5A, B, C). This time, these distortions are used to 
represent the peristaltic motion experienced by the intestines (Fig. 5D, E). The upper and 
lower microchannels are 150µm high x 1000µm wide, and are separated by a 30 µm thick 
PDMS membrane that has 10 µm pore size. Caco-2 cells were used to represent the intestinal 
epithelial cells, and were cultured on a PDMS membrane coated with ECM. Trials consisted 
of a Transwell plate for control and the microfluidic device containing just fluid flow, just 
mechanical distortion, and both. Results showed faster and higher quality Caco-2 cells in the 
trials using the microfluidic device. In the absence of fluid flow, the cells in the microfluidic 
trial resembled those in the Transwell plate.  Additionally, the trial containing both fluid flow 
and mechanical distortion grew cells containing folds that resembled intestinal villi. To 
simulate the GI tract more accurately, cells obtained from a strain of Lactobacillus 
rhamnosus GG (LGG) were used to simulate the microbes native to the intestines.  The co-
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culture displayed greater integrity than the Caco-2 monolayer in the prior trials when 
exposed to fluid flow and mechanical distortion on the microfluidic chip. Therefore, this 
design was a success in introducing two variables to a gut-on-a-chip model: the integration of 
microbial cells native to the intestines and the dynamic motions inherent in the organ. Kim 
has explored these ideas further in other research papers [41]. 
 
Fig. 5. Layout for Gut-on-a-chip, with a) two co-current microchannels containing a 
membrane with cultured gut epithelium. Two vacuum chambers are located on either side of 
the device. B) An aerial view is shown of the actual device. C) A cross-sectional view is 
shown, with an aerial view of the membrane. D) When the vacuum chambers are active, 
mechanical strain is exerted on the device (upper two images). Cells showed that they would 
deform due to mechanical strain. The image on the bottom left circled in red is an epithelium 
cell before strain and the image on the bottom right circled in blue is an epithelium cell after 
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strain. Note the image to the right showing an overlap image of the two, with the deformed 
cell clearing showing a larger width. E) Graphical results of the strain of both the substrate 
and the cells as a function of the applied pressure of the vacuums [40]. 
 
In contrast to Kim et al., the experiment done by Kimura et al. [42] used polarized 
Caco-2 intestinal cells in their microfluidic system. Polarized cells are known to mimic 
human organs, especially the human intestine, with much better accuracy.  The developed 
microfluidic system was able to have long-term perfusion within the cell culture, as well as 
integrated optical fiber inserts used for fluorescent measurements within the device. The 
device contained two PDMS layers separated by a semipermeable membrane coated with 
collagen.  A micropump controlled by a stir-bar was used to induce circulation of the 
medium. Once again Caco-2 cells were used to represent the intestinal cells and were 
cultivated on the apical side of the membrane. On the ninth day of cultivation, a confluent 
monolayer of cells was observed over the membrane. The cells were able to be cultured for 
up to 30 days and formed a tight monolayer. Transportation qualities were recorded by 
introducing rhodamine 123 into the medium, along with fluorescent beads, and recording the 
effects through the optical fibers.  The results showed flow capable of long-term perfusion 
within the system. The functionality of the device and the measurements found through the 
results of the rhodamine 123 show that this has the potential to be a useful platform for drug 
screening as well as toxicity testing.   
Some microfluidic systems are complex or have operating parts that not everyone can 
use. For this reason, it is important to think about simpler designs for microfluidic systems. 
Imura et al. [43] developed a microchip-based system that mimicked the human intestine. 
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They had a microfluidic system to evaluate the intestinal absorption, with less cells and 
samples used and a shorter testing time. The design of the system was a two-tiered 
microchannel separated by a monolayer of Caco-2 cells that are cultured on a permeable 
membrane. The device had two PDMS sheets, each with its own microchannels that were 
1.5mm in width and 200µm in height. The channels connected the upper and lower side of 
the PDMS sheets together. The upper channel worked as a microchamber for the cell culture. 
The membrane was made of a polyethylene terephthalate sheet that had 1µm sized pores and 
was coated with type I fibrillar collagen. Permeation tests were done to test the drug 
permeability of cycliphophamide (CPA), using Lucifer yellow as a fluorescent marker. They 
also set bubble traps in the injection ports to prevent incursion into the chip. Since past 
structures had leaked the Lucifer yellow to the lower channel because of loose PDMS 
sealing, a new design was made. In this new design, the lower PDMS sheet and the 
membrane were tightly bonded to avoid leakage onto the other channels. Due to the cells 
becoming damaged because of unstable medium flow, the group cultured the cells statically 
and the medium was replaced on a daily basis. The Caco-2 cells formed a confluent cell 
sheet, and the Lucifer yellow could not permeate the membrane, while the CPA did. Good 
results were obtained with a lower flow rate; however, it also proved to be very time 
consuming. The Caco-2 cells reached confluence after 3 days and then remained this way for 
10 days in the microchamber. When compared to conventional in vitro experiments, this 
system had practical characteristics of intestinal absorption. 
Drug testing is one of the most important factors in intestinal microfluidic 
applications. Although many groups have used drugs for testing, none of them have used an 
array of drugs to study the effects they have in relation to each other. Yeon et al. [44] 
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developed a microfluidic device to test drug permeability in the intestinal epithelial cell 
membrane. Researchers looked at 10 different drugs in order to test their permeability and 
compare the results with in vivo permeabilities. Instead of a membrane, the device trapped 
Caco-2 cells in microholes and measured the permeability of the drugs from there. The 
microfluidic device consisted of channels, each with an inlet and outlet, and a microhole 
array separating the two channels, and a channel for mixing. The microholes are 3µm in 
diameter, 5µm in height, and 30µm in length. The microchannel height was 25µm and most 
animal cells with a diameter of 5-15µm could be trapped. The Caco-2 cells are imported into 
only one of the inlets, while a buffer is imported through the other.  Different flow rates from 
the two channels created a pressure difference that trapped the cells once they reached the 
microhole array. Once this occurs, the drug intended for testing is imported through the inlet 
originally containing the buffer. The drugs are absorbed by the cells in their channel, and 
travel through the mixing channel and into the outlet. The 10 drugs that were used for the 
experiment were: propranolol, naproxen, furosemide, antipyrine, verapamil, atenolol, 
piroxicam, hydrochlorothiazide, cimetidine and carbamazepine. The Peff values that were 
measured in the microfluidic device were not the same as in vivo; however, they were still 
highly correlated with the permeabilities in the human intestine. This system reduces the 
assay time due to a non-complex system, and because there is no cellular membrane. The 
results found here has the potential to be used in predicting actual human permeability values 
of drugs, as well as a tool for drug discovery and toxicity testing. 
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2.3.4 Kidney 
The renal transporters are located in the apical and basolateral membranes of the tubular 
epithelial cells. The effect of fluid shear stress on the cells is less understood than other major 
cells [45]. The renal epithelial cells experience mechanical forces due to variations in the 
urinary flow rate.  
With toxicity being a main interest in the drug testing field, the kidney has been an 
organ of increasing interest for such tests. The kidney is exposed to fluid shear stress and it 
acts as a filtration system for the blood, as well as a vessel for the removal of toxins. The 
kidney transfers the toxins to the bladder, where they are then removed from the body during 
urination. Recall that Shintu et al. [20] used the liver and kidney, as well as cell co-cultures, to 
study their metabolic responses to various toxins.  However, this section will focus on 
research done solely on the kidney [46].  One of those is Baudoin et al. [47], who developed a 
microfluidic microchip that contained functional living cell microchambers that allowed for 
continuous cell feeding and waste removal. Their experiment consisted of a Madin Darby 
Canine Kidney (MDCK) cell culture on a PDMS-based cellular microchip that can be used 
for in vitro renal applications. Additionally, a toxicity study was performed on the microchip 
for the demonstration of large-scale toxicity applications. The group coated the PDMS chip 
in Fibronectin (extracellular matrix protein). The first PDMS layer with the microstructures 
contained a series of 300µm x 300µm x 100µm microchambers and 400µm x 150µm x 
100µm microchannels, which were all contained inside a cell culture chamber. The second 
layer of PDMS was used to close this cell culture chamber. Culture media was brought into 
the microchip system through a culture medium tank, and the flow was induced through a 
peristaltic pump. These devices were formed as a circuit, thereby creating a perfusion loop. 
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For toxicity tests, ammonium chloride was used. The initial experiments tested the viability 
of cells in the system as it ran inside a CO2 incubator for various flow rates (0, 10, 25, and 50 
µL/min). The results showed it was able to run while keeping a viability above 90% for 
almost all flow rates, except for at 50µL/min. At 50µL/min, the cell detached from the 
surface after a 24 hour perfusion and viability was found to be below that of 10%. Cell 
density tests showed that at static conditions, the number of cells stayed roughly the same, 
regardless of their initial count.  At flow conditions, slight proliferation of cells was observed 
at flows of 10µL/min and 25µL/min. The addition of ammonium chloride as a toxicity agent 
caused the reduction of cell proliferation.  This reduction was most prevalent in the 
10µL/min trial. The addition of ammonium chloride also led to an increase in the 
consumption of glucose and a decrease in the production of ammonia.   
The integration of fluid shear stress is an important factor that can increase the 
relevance of an in vitro model. Jang et al. [48] developed a multi-layer microfluidic device that 
utilizes fluidic shear stress for a more complete renal model. They used primary rat inner 
medullary collecting duct (IMCD) cells as their model to be cultured inside the microfluidic 
channel. A fluidic shear stress was applied to the device to generate a realistic environment 
for the cells. The device consisted of two layers of PDMS, with a polyester porous membrane 
between them.  The bottom layer of PDMS was used as a reservoir, while the top layer 
contained a microfluidic channel that would be used for fluid flow. After 3 days of culture, 
the cells were brought into the system and a fluid shear stress was applied for 5 hours using a 
syringe pump. After the shear stress was applied, 1mM of hydrogen peroxide solution was 
added to the fluid regions to test the cell viability. Hydrogen peroxide was also added to a 
control culture that was cultivated on a glass surface separate of the device. The results 
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showed that after 2 hours of treatment, the device under fluid shear stress already displayed a 
significantly higher viability than the glass control. Additionally, the system showed accurate 
cell separation associated with its cell polarization. Molecular transport was also analyzed by 
applying vasopressin and aldosterone into the lower PDMS reservoir to induce hormonal 
stimulations into the system. Vasopressin is able to induce water transport, while aldosterone 
induces NA transport. Both of these results agree with in vivo expectations. This system can 
be used as a model for diseases like diabetes or edema, as well as a model for studying renal 
physiology. 
In the year 2010, Jang studied the kidney cells and showed the polarization and 
transport of the primary rat inner medullary collecting duct (IMCD) cells as well as the 
application of fluid shear stress (FSS). Now in the year 2011, Jang et al. [49], developed a 
‘collecting-duct-on-a-chip’ to further investigate the effects of changes within a renal 
environment. The role of the collecting duct in the kidney is mainly to maintain homeostasis 
of fluids through transportation across its membrane. Specifically, the role of the protein 
aquaporin-2 (AQP2) was observed under these altered conditions due to the major role it 
serves in water transport across the membrane.  Additionally, the role of the actin 
cytoskeleton present in in vivo collecting ducts (F-actin) is explored in the model.  Like their 
previous design, the main components that made up the chip consisted of a PDMS reservoir 
and a PDMS layer complete with microchannels for active fluid flow, as well as a polyester 
membrane separating them. Fluid shear stress, hormonal stimulation, and an osmotic gradient 
across the membrane will serve as the active changes within the system. Fluid shear stress at 
1 dyn cm-2 and arginine vasopressin stimulation (AVP) were applied in the microfluidic chip 
for trials consisting of F-actin within the IMCD cells. A strong fiber network was observed 
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roughly 1 hour after the start of the trial, with a slow depolymerization occurring up until 
hour 5, when the F-actin was fully depolymerized.  It was also observed that if system was 
left undisturbed after depolymerization, the F-actin would repolymerize after roughly 2 
hours. Additionally, the application of an osmotic gradient was shown to lead to a full F-actin 
depolymerization. This system can be used as a tool for drug screening of the regulation of 
AQP2 as well as being an important model for fluid homeostasis. 
Most recently, Jang et al. [50] made a microfluidic device that mimicked the functions 
of the human proximal tubule using primary human kidney epithelial cells. Although they 
only used one type of cell, their research brings forth more information that is needed to help 
the problem of accurate drug development. Their system, just like others, can be used to 
replace two dimensional cell culturing and animal testing for the ability to test for toxins in 
organs. The device shows many similarities to their previous design [49]. Once again, the 
main components consisted of a lower reservoir and an upper microfluidic channel with a 
porous membrane containing ECM collagen separating the two. The cells were cultivated on 
the porous membrane, in which well-defined monolayers were observed after 3 days for both 
static and fluid conditions. The addition of fluid shear stress created an even more realistic 
cell layout, with a system of cell columns consistent with their in vivo cell polarity (Fig. 6.). 
Analysis of the system showed that the levels of albumin uptake, expression of brush-border 
alkaline phosphatase, and glucose transport were greatly increased when flow was introduced 
into the system. To observe toxicity effects, the cells were treated with cisplatin for 1 day and 
then were allowed to recover by keeping them drug free for 4 days. The magnitude of 
recovery was significantly higher in the system containing flow. The use of primary human 
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kidney epithelial cells, along with a model used in static and dynamic conditions, presents a 
method that shows promise for renal toxicity analysis. 
 
 
Fig. 6. Design layout for the device, showing A) a cross-sectional view. The device mimics 
the human proximal tubule of the kidney (pictured below). Human proximal tubuluar 
epithelial cells are cultivated on top of the membrane, with tubular flow occurring on the 
apical section, and interstitial fluid located on the basolateral section. B) The device shown 
layer-by-layer. Two design consists of an upper layer containing a microfluidic channel and 
a lower layer containing a fluid reservoir [50]. 
 
Since fluid shear stress is very important in the function of the kidneys, Frohlich et al. 
[51] developed a microscale tissue modeling device (MTMD) to represent an accurate renal 
system.  This device focuses on utilizing fluid shear stress and a topographical pattern to 
mimic its in vivo counterpart. The device consisted of a lower silicon plate that contained 
sub-micron topographical features such as grooves and pitches, and an upper PDMS layer 
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containing a microfluidic path. The human renal proximal tubule cell line HK-2 was chosen 
to represent the tissue. The HK-2 cells were stained with ZO-1 fluorescence to analyze the 
tight junction formation. Blank substrates in the presence of FSS showed a much lower ZO-1 
intensity and a more disorderly array of cell structure.  Topographic substrates without FSS 
showed a higher ZO-1 intensity and a better array of the cell layer. In the presence of both, 
the cells showed a well-defined tight junction with good intensity.  Therefore, while FSS 
seems to play a bigger role in the modeling of the kidney, a combination of both yields the 
best results. 
The role F-actin plays in the transportation of nutrients across the membrane was also 
analyzed by Ferrell et al. [52], who used electrodes designed to take TEER measurements to 
analyze a working kidney bioreactor under fluid shear stress conditions. TEER measurements 
have shown to provide excellent inside into the tight junction permeability properties of a cell 
culture. Additionally, transportation properties were analyzed, with special focus on the 
structure of tight junctions (ZO-1) and cilia formation (acetylated α-tubulin) within the cells, 
and the F-actin cytoskeleton array that facilitates transfer. The device consisted of an apical 
chamber complete with 8 microfluidic channels and a basolateral chamber used as a 
reservoir. An array of 200µm diameter posts was used to support the membrane on the 
bottom chamber and allow fluid transport. A polycarbonate membrane was connected to 
separate the two chambers. A perfusion circuit was created, consisting of the bioreactor, a 
perfusion pump, and a medium reservoir, all connected through silicone tubing. For TEER 
analysis, electrodes were inserted within the tubing, with the ends exposed within the 
bioreactor. Additionally, all trials were conducted within an incubator. A shear stress of 1 
dyn cm-2 was used for fluid shear stress trials.  Both human renal epithelial cells (HREC) and 
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MDCK cells were cultivated on the membrane. Initial culturing results showed that the 
MDCK cells were able to form a monolayer within 3-5 days, while the HREC cells took 10 
days. Staining techniques were used to analyze the formation of tight junction proteins, cilia, 
and F-actin (HREC only). Both ZO-1 proteins and acetylated α-tubulin were observed in the 
model, showing well-defined borders and distinct formations (Fig. 7a-b). Additionally, the 
role of F-actin in static conditions showed a normal layout of F-actin (Fig. 7c), while fluid 
shear stress conditions showed the F-actin surrounding the cell (Fig. 7d). It is believed that 
this is a normal response of the cytoskeleton to shear stress and is similar to what happens in 
the cells of humans. The system was then monitored with the addition of Ca2+ into the 
medium, which is known to have a positive effect on the structure of tight junctions. A 
switch technique was used to measure transient changes, where the system would switch 
between using a medium containing normal levels of Ca2+ to low levels of Ca2+.  After 
analysis, normal levels of Ca2+ were restored and the system was allowed to recover. The 
switch from normal to low levels of Ca2+ showed a TEER that contained 45% of its original 
resistance. Using inulin as a marker, the results showed a large increase in leakage rate when 
the switch to low Ca2+ levels was made (from 0.09 ± 0.03 µg cm-2 min-1 to 0.39 ± 0.09 µg 
cm-2 min-1), showing the potential breakdowns of cell interactions when transient changes are 
applied. 
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Fig. 7. Immunofluorescence staining results depicting the formation of a) MDCK monolayer 
and b) HREC monolayer, each containing well-defined tight junctions (green outline) and 
primary cilia (red dots addressed by arrows).  Additionally, HREC was stained for F-actin 
analysis under c) static conditions and d) fluid shear stress conditions. Arrows in Fig. 7c 
indicate F-actin fibers. Scale bars in Fig. 7b and Fig. 7d are at 25µm [52]. 
 
Analysis of mass transfer has also yielded results [53]. Ramello et al. [54] investigated 
the properties of mass transfer in a microfluidic kidney model. They also analyzed the 
transportation by using different drugs. The study used MDCK cells on a polyethersulfone 
(PES) membrane inside a PDMS chip. The chip contains an upper and lower chamber, each 
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containing an inlet, outlet, peristaltic pump, and filtration chamber in co-current circulation. 
This was done to create a system in which one chamber contains a reservoir of filtrate while 
the other contains retentate. The retentate circulation would initially contain the molecule 
used for inspection, while the filtrate circulation would capture the filtered molecule. 
Molecules used for this experiment were chosen based on their variety in size.  Caffeine was 
used as a small marker, vitamin B12 was used as a medium marker, and albumin was used as 
a large marker. The value of cell membrane permeability before mass transfer studies was 
measured as being equal to 1.8 ± 0.2 mL/(min cm2 bar), and the value without cells was 9 ± 3 
mL/(min cm2 bar). Trials involving mass transfer were compared with mathematical models, 
with cells and without cells on the membrane. The results showed an inverse relationship 
with molecular weight; there was a notable increase in mass transfer as the molecular weight 
decreased. Mass transfer through a membrane without cells yielded higher rates of mass 
transfer for all trials. When treating the cells as a separate diffusive layer, the mathematical 
models fit the experiment results perfectly. In an attempt to model toxicity in the system, 
acrolein was used at varying concentrations.  For each molecule tested, there appeared to be a 
threshold in which acrolein did not play a factor in the mass transfer of the system.  The 
larger the molecular weight, the higher the threshold. Above this threshold, the diffusive 
coefficient was found to be higher than trials without acrolein. A second threshold was 
observed, in which surpassing it yielded a time-dependent mass transfer rate. The 
permeability of the membrane was measured after the acrolein trials, which revealed an 
increased permeability of 8 mL/(min cm2 bar). Thus, these experiments showed the effects of 
molecular weight and toxicity on the permeability and mass transport properties of the 
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system.  These results agreed with past research and mathematical models and have shown 
that they can be a useful model for modeling mass transport on a renal biochip. 
 
2.3.5 Heart 
The function and development of the heart mainly depends on the response of the cardiac 
cells and the mechanical stress. In order to have new successful drugs and medicine, it is 
important to understand the biological functions of the heart. Current cell culture systems fail 
to accurately represent the physical, mechanical, and biological functions of the heart. There 
have been studies that have tried to model the heart; however, most are two dimensional, and 
although they do show some mechanical properties, they are not the best for accurately 
mimicking the human heart as they do not have complete heart properties and do not allow 
for fluid flow or similar work [55] . For this reason, three dimensional microfluidic systems for 
the heart are being explored as well.  
Many groups have designed various systems to model the human heart and to mimic 
the key mechanical functions and properties [56]. Due to the advantages of 3D microfluidic 
systems, there has been a shift towards using these designs to represent cardiac situations [57]. 
Giridharan et al. [58] developed a model designed to replicate physical loading in the left 
ventricle. This microfluidic cardiac cell culture model (µCCCM) contains a cell culture 
chamber, a pump, a collapsible pulsatile valve, and an adjustable hemostatic valve.  The cell 
culture chamber consists of a PDMS membrane between two polycarbonate plates, milled 
with microfluidic channels to create perfusion through the membrane. The embryonic 
cardiomyoblast cell line H9C2 was used for cultivation on the membrane. The pump serves 
the purpose of supplying flow, and therefore shear stress and fluid transport, to the system. 
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The pulsatile valve is used to produce mechanical stress into the system in the form of 
pressure build-up in the cell culture chamber, resulting in the stretching of the membrane. A 
closed valve builds pressure while an open valve relieves pressure, thereby being capable of 
representing cardiac preloading. The hemostatic valve is used to control flow resistance, and 
is a representation of afterloading. These devices are connected as a circuit to provide 
circulating fluid flow. This device was first tested by applying different levels of pressure for 
a variety of membrane thicknesses.  The strain was found to be inversely proportional to 
membrane thickness, displaying a 20% strain for a 139µm thick membrane and 60% for a 
93µm thick membrane.  Next, the device was characterized for normal conditions, as well as 
for abnormal conditions such as: heart failure, hypertension, hypotension, tachycardia, and 
bradycardia. The simulation of cardiac disorders was done through the programmable valves 
connected to the system. Values obtain from these trials depict fairly comparable results with 
their in vivo counterpart. When comparing the cellular make-up between static trials and the 
trials within the µCCCM, results showed that the static culture make-up resembled 
fibroblasts, with randomized F-actin, while the µCCCM displayed a rectangular, boxy make-
up with aligned F-actin. This shows the capabilities inherit in modern microfluidic cardiac 
models, especially when considering abnormal heard conditions. 
When dealing with in vitro microdevices for tissue engineering or drug delivery [59], 
external power sources are depended upon to supply energy into the system.  However, if the 
device requires implantation into an in vivo source, external power sources must be 
eliminated. Tanaka et al. [60] fabricated a micro spherical pump made from cardiomyocytes to 
represent the heart functions. The hollow sphere was created by inserting a capillary tube 
through the entirety of a sugar ball, so that both ends of the capillary could be observed 
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outside of the ball.  A layer of PDMS was applied around the sugar ball, and the capillary 
tube was pulled back to allow a second capillary tube to connect to the other side, and both 
tubes were glued into place. A pump was applied through one of the capillary and water was 
introduced to dissolve the sugar.  This resulted in a hollow sphere with a thickness of 250µm 
(Fig. 8a). Rat cardiomyocyte cells were cultured and placed on the surface of the PDMS 
sphere. Spontaneous pulsating was observed within one hour of incubation, which eventually 
became periodic beating (Fig. 8b).  Fluoro Sphere particles were introduced into the medium 
for tracking. The results were determined with a particle displacement data set which 
estimated the parameters for the performance of the fluid bio-actuation. The following 
equation was used to describe the change in microchannel volume as a function of the change 
in chamber volume:  
Δv=1/2ΔV     (2) 
where Δv is the volume change in the microchannel and ΔV  is the volume change in the 
chamber. Using Δv=0.5𝑥𝜋r2 as an approximation due to its circular cross-section, where x is 
the displacement of particles near the capillary center and r is the inside radius of the 
capillary, ΔV was found to be 2.2nL.  From there, the following equation was used: 
Q=f ΔV    (3) 
where Q is the flow rate and f is the beat frequency. They found that f was 0.6Hz at 37º C, 
which resulted in a final Q value of 0.047 µL min-1. Long-term trials showed that the device 
could be functional for up to 5 days. They compared it to other typical micro chemical 
systems and showed that it is possible to use the system Tanaka et al. made in micro 
chemical or biochemical applications. They confirmed that their device was flexible and 
biocompatible and very similar to other polymer pump actuators. They concluded that if their 
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heart device functioned continuously for at least 5 days, the cells of cardiomyocytes that 
were inside the sphere would live for that amount of time as well. They stated that this can be 
used to mimic animal hearts; however, it is worth noting that there are multiple chamber 
valves and walls required for this process. To do this they used an in situ laser photo-
fabrication technique. These results and their microspherical heart pump are very important 
as it is a step towards having electric powerless bio-actuators for fluids in implants and also 
for micro model cardiovascular circulatory systems for monitoring applications. 
 
Fig. 8. Diagram of the micro spherical heart pump, shown in A) a full view, diplaying the 
components of the device and medium brought in through port A and expelled through port 
B. Additionally, B) a cross-sectional view is shown. The layer containing the rat 
cardiomyocytes can be seen, with red arrows shown to display their contracting nature on 
top of the PDMS sphere [60]. 
A different study to that done by Giridharan et al. and Tanaka et al. was done by Li et 
al. [61], who fabricated a microfluidic chip that uses integrated acoustic wave sensors to 
analyze cardiomyocyte contraction. The sensor works by applying a voltage to the electrodes 
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located on both sides of a flat quartz crystal plate. The voltage induces acoustic waves from 
the crystal due to the piezoelectric effect. These acoustic waves will be produced in the 
thickness-shear mode (TSM) and applied to the cardiomyocyte cells. Any change in stiffness 
will result in a modified resonant frequency. This method can be used to identify pulsating 
properties of the cells. The device consists of an upper glass plate milled with microfluidic 
channels and a bottom quartz crystal plate acting as the TSM sensor. Cells were fit into the 
channels of the glass plate. Data showed that the device without the channel plate was 
capable of reacting to changes in the system for all parameters.  Changes in the system 
include additions of cell suspension and a bath solution. The parameters were shown to make 
corresponding changes at the intervals at which the changes in the system were applied. The 
experiment was then run using the channel plate.  The results showed mixed results that only 
proved that the system wasn’t fully capable of responding to the acoustic waves. The group 
believes that offsetting contractions may have been one of the underlying problems in the 
experiment, and therefore a shorter interval between data points may be able to rectify this 
problem. 
While not falling into the classic mold of organ-on-a-chip systems, the method of 
testing extracting organ tissue instead of cultivating cells is another potential method for 
understanding organ function in vitro. Owaki et al. [62] proposed a microvascular connection 
method called the “suction-induced vascular fixation method” or SVF method. They were 
able to use tissue from an extracted chick heart and connect it to their microfluidic system. 
The SVF method consists of using a suction technique to bring all the blood vessels through 
a microfluidic device.  This constrains the vessels so that they are easily manipulated and can 
be analyzed with less degrees of freedom. The microfluidic device consists of a PDMS layer 
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containing holes designed for integration with the blood vessels of the chick heart, as well as 
a perfusion chamber to maintain functions of the organ. Due to the variability and uncertainty 
of blood vessel diameters, the device allows several vessels through one hole if the vessels 
prove to have a smaller diameter than expected, and can also be rejected if the vessel 
diameter is too large. While the main goal of their experiment was to design an alternative 
method to handle the analysis of organ tissue, an addition test was done in which a solution 
was sent through the device and into the embryonic heart.  The results showed that a periodic 
circulation could be achieved through this method, and the heart was able to periodic beat 
using this method. 
 
2.3.6 Vasculature  
Endothelial cells that line blood vessels are designed for functions such as: facilitating blood 
flow, enabling nutrient transfer through the vessel, and regulating surrounding tissue growth 
[63]. A viable microcirculation is required in in vitro models if we are to interconnect organs.  
This will be especially important if a “human-on-a-chip” design is created. However, this 
section will focus on a microfluidic model for isolated vasculature. It is vital to have a 
realistic in vitro model for drug development and the study of cell-cell interactions. 
Research into 3D in vitro vasculature has produced a variety of results [64].  However, 
the design of functional artificial vasculatures has been a difficult hurdle to overcome.  
Borenstein et al. [65] have specifically addressed this issue in their design. The microchip 
design displayed one inlet and outlet, with a bifurcating microchannel network stemming 
from each end and joined such that the design showed a symmetric pattern. To better mimic 
human vasculature, all channels were designed with circular cross-sections, and each new 
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generation of bifurcation had a smaller cross-sectional area than the last (Fig. 9). The 
diameters chosen for each subsequent channel were based off of Murray’s Law. Polystyrene 
was used as the material for the chip due to its stability and a better understanding of the 
surface properties. Two layers, each containing the network with cross-sectional channels, 
were created using an electroplating technique. Human umbilical vein endothelial cells 
(HUVEC) were cultivated on the inner surface of the channels. Results showed a stable and 
consistent monolayer throughout the channels. Thus, the goal of creating a microfluidic chip 
capable of accurately representing human vasculature proved successful. While flow was not 
examined in this experiment, the circular cross-sections and smooth transitions between 
bifurcations and diameter changes have potential for use in microfluidic vasculature chip 
designs. 
 
Fig. 9. Image taken of the device. A network of bifurcating channels, each level containing a 
diameter smaller than the last, is shown. The scale bar is displayed at A) 1mm and B) 500µm 
[65]. 
In pursuit of a physiologically similar vasculature model, considerations such as 
multi-cell interaction and dynamic stress on the system should be considered. The design 
created by Srigunapalan et al. [66] looked at the effects of shear stress, monocyte-EC adhesion 
through TNF-α stimulation, and monocyte transmigration on a microfluidic vasculature 
system. The device consists of two PDMS layers, with the top layer displaying a straight 
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microchannel and the bottom player displaying an S-shaped microchannel. A polyethylene 
membrane containing 8µm pores is used to separate the two layers. Circulation of flow was 
provided through a peristaltic pump that would take media from a reservoir compartment and 
feed it through a damper, followed by the microfluidic chip, then back into the reservoir, 
completing the cycle. The purpose of the damper was to force continuous flow (as opposed to 
pulsatile flow) into the chip. Porcine aortic endothelial cells (PAEC) were chosen for the EC 
and were cultivated on the top of the membrane. Initial trials tested this system under static 
and dynamic conditions, with dynamic conditions providing a shear stress of 20 dynes cm-2. 
Results showed elongation of the PAEC for dynamic trials.  Further trials introduced TNF-α 
stimulation into the culture, followed by monocytes (RAW264.7 cells) applied with 
fluorescent dye. Monocyte adhesion was tested as a function of both TNF-α stimulation and 
its static/dynamic state.  Results showed that TNF-α was the biggest factor in monocyte 
adhesion, while the trials under fluid shear stress proved to have slightly better adhesion 
capabilities than their static counterparts. Trials done for testing transmigration used THP-1 
cells for monocytes. THP-1 was introduced in the top channel and adhered to the PAEC. 
Transmigration effects were observed through the membrane as the monocytes travelled into 
the bottom channel. Stimulus effects were observed with the protein MCP-1, introduced 
solely in the bottom channel. Results from these trials showed that the introduction of MCP-1 
lead to a roughly ten-fold increase in the number of transmigrated monocytes per square 
millimeter. Therefore, the effects of cell-cell interaction and stimuli replicated various 
scenarios in a microfluidic vasculature chip. The best conditions for in vitro monocyte 
adhesion are with TNF-α stimulation and fluid shear stress conditions, and the best 
conditions for transmigration are with MCP-1 stimulation. This shows how additional 
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considerations within the device to mimic in vivo vasculature have the potential to produce 
the best results. 
 
2.3.7 Other Organs 
While the organs with the most prevalent research have been highlighted in previous 
sections, organ-on-a-chip systems have the potential to be used for many different organs. 
Researchers have been able to branch out in this respect and explore different ideas in unique 
systems tailored to their chosen organ.  Additionally, microfluidic organ-on-a-chip systems 
with cancerous organs will be explored, as well as multi-organ chips aimed to produce results 
working towards a body-on-a-chip. 
 
2.3.7.1 Bone marrow 
Torisawa et al. [67] designed a working bone marrow-on-a-chip device to replicate in vivo 
functions and study the effects of radiation-induced toxicity. The design features a PDMS 
cylindrical ring containing demineralized bone powder (DBP) and bone morphogenetic 
protein 2 and 4 (BMP2, BMP4). A PDMS cap was placed over the top cavity of the ring to 
better regulate adipocytes for better hematopoiesis. Cultivation of these materials within the 
device was performed in vivo through implantation within a mouse. After 4-8 weeks, new 
bone structures were formed with a marrow inner region showing signs of cellular activity. 
The most prominent cells within the marrow were hematopoietic cells. Cultivation for 8 
weeks within the mouse yielded the best results, with an array of cells that mimicked 
naturally grown bone marrow. Once the artificial bone marrow was removed from the rat, it 
was placed within a microfluidic PDMS chip (Fig. 10a-b). This chip contained PDMS layers 
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containing microchannels designed above and below it. Two porous membrane layers were 
positioned between the layers containing microchannels and the culture chamber. The device 
showed it was capable of maintaining its structure and function for up a week with a medium 
containing cytokines. In comparison with naturally grown bone marrow extracted and 
cultured in a static system, the results from the microfluidic system showed similar 
functionality and viability of long-term hematopoietic stem cells (HSC). Freshly isolated 
bone marrow from both systems displayed the highest number of long-term HSC, with each 
subsequent day showing a decrease in that value.  Additionally, the naturally grown static 
trial also displayed a significant increase in progenitor cells after a period of time compared 
to freshly isolated bone marrow. Further trials exposed the microfluidic bone marrow device 
to γ-radiation to observe the toxic effects on the organs functionality and cell viability. For 
control purposes, a system of the previously mentioned static culture with naturally grown 
bone marrow, as well as live mice, were tested as well. The various cell viabilities were 
tested at different radiation dosages. The results showed an inverse relationship between γ-
radiation dosage and cell viability for the HSC, progenitors, lymphoids, and myeloids. 
Granulocyte colony-stimulating factor (G-CSF), shown to inhibit radiation effects and 
promote recover of bone marrow in mice, was also tested in this fashion. Results showed that 
G-CSF did indeed provide a higher cell viability for bone marrow cells. Thus, the system was 
able to provide in vitro bone marrow functionality under normal conditions and toxic 
conditions that are comparable to in vivo results. Future toxicity tests with bone marrow 
diseases have the potential to be utilized using this technique. 
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Fig. 10. A) Process of obtaining bone marrow cells highlighting the several key steps: 
implanting the device containing bone-inducing materials within the mouse, letting it 
cultivate within the mouse for 8 weeks, and introducing the eBM (engineered bone marrow) 
into the chip. B) Images of this process can be seen, shown before implantation (left), after 
extraction from the mouse (middle), and the chip containing the eBM in its entirety. Scale 
bar is at 2mm [67]. 
 
2.3.7.2 Brain 
Delivery of drugs and nutrients into the brain is regulated by the blood-brain barrier (BBB).  
On the blood side of the barrier lies a complex array of vascular endothelial cells, and on the 
brain side lies the central nervous system. Issues maintaining functionality of the BBB can 
result in neurological disorders.  Thus, it is important to understand and test the effects that 
drugs might have on the BBB through in vitro design.  Therefore, with respect to the brain, 
most microfluidic models will feature a BBB-on-a-chip [68]. Griep et al. [69] designed a 
working BBB-on-a-chip and tested its functionality through TEER measurements. Two 
b
a
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PDMS layers were constructed with a straight microfluidic channel that was positioned so 
that the top channel was perpendicular to the bottom channel. Additional grooves were 
created to fit in the electrodes for TEER measuring. A polycarbonate membrane was 
positioned between the two layers.  Human brain endothelial cells (hCMEC/D3) were 
cultivated in the top channel and showed a confluent monolayer within 1 day. TEER results 
showed similar results between a static culture and the BBB chip, both displaying tight 
junctions and a confluent monolayer. Next, the effects of fluid shear stress on the 
hCMEC/D3 were tested.  After 3 days of normal function in the device, the BBB chip was 
exposed to shear stress of 5.8 dyn cm-2 for 18 hours. Results showed that the TEER value 
triple during the duration that shear stress was applied to the system. Afterwards, the effects 
of TNF-α stimulation was tested on the device. Directly following the 18 hours of exposure 
to fluid shear stress, 1 ng/ml of TNF-α was introduced to the system for 2 hours. Results 
showed that the TEER value dropped 10-fold when TNF-α was introduced. While this may 
show that the effects from TNF-α in the system make a much bigger impact than fluid shear 
stress, it is important to note that increasing TEER values is much more difficult to achieve 
than decreasing, since even the slighted gap in the cell monolayer can significantly reduce 
TEER values [3a]. This experiment shows the capabilities of BBB models, with research 
already capable of considering the biochemical and mechanical factors that may contribute to 
its function. 
 
2.3.7.3 Spleen 
In the human body, the spleen serves the role of filtering blood, recycling red blood cells, and 
containing a reserve of white blood cells.  While a spleen can be removed from the body 
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without suffering fatal injuries, it still serves important roles; of which an in vitro 
understanding can benefit, especially with an ultimate goal of creating a “body-on-a-chip.”  
A “splenon-on-a-chip” design was created by Rigat-Brugarolas et al. [70].  This design mimics 
the red pulp area of the spleen by creating a fast-flow layer and a slow-flow layer.  The fluid 
going through the slow-flow layer travels through a straight channel representing the 10% of 
blood that goes through a filtration process, where unhealthy red blood cells are destroyed.  
This channel also contains an area filled with a pillar matrix, thereby impeding the flow and 
increasing the density in that area, representing a reticular mesh observed in an in vivo 
spleen. The fluid going through the fast-flow layer travels in a zig-zag pattern representing 
the rest of the blood going through the bypass of the filtration process. This device is 
connected to a syringe pump, providing flow at 5 µl min-1. Deformability studies can be 
performed on the device, with cells incapable of deforming showing constriction in the 
channels. Initial tests in the microfluidic system looked at the differences in deformability 
between new and aged red blood cells (RBC’s). Results showed that ages RBCs showed less 
deformability than new RBCs. The infected red blood cell (iRBC), Plasmodium yoelii-GFP, 
was then tested and compared to healthy RBCs. The results showed that healthy RBCs had a 
deformation measurement of roughly 19%, whereas the unhealthy iRBCs had a deformation 
measurement of roughly 34%. This device shows a unique way of representing a 3D 
microfluidic spleen capable of identifying pathogens based on their deformability. 
 
2.3.7.4 Cancer/Tumor 
Modeling in vitro microfluidic chips to represent in vivo cancerous situations is a popular 
area of research.  Models involving lung [71], breast [72], prostate [73], pancreas [74], brain [75] 
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cancer have been created. Song et al. [76] designed a microfluidic device to replicate the 
functionalities of breast cancer cells in a vasculature system.  The design consists of two 
PDMS layers containing microchannels, and a polyester membrane positioned between the 
layers.  The microchannel on the top layer contains a funnel-shaped inlet with a straight 
channel, while the bottom layer contains two straight channels located perpendicular to the 
top channel (Fig. 11A, D). Human dermal microvascular endothelial cells (HDMEC) are 
cultivated on the top of the membrane (Fig. 11C).  Trials consisted of introducing 
chemokines (CXCL12) contained in the medium through the lower channels, with breast 
cancer cells (MDA-MB-231) circulating through the top channel, with a focus on the 
adherence of the cancer cells on the endothelial cells in the overlapping channels (Fig. 11B, 
E, F). One of the contributing factors to cancer cell adhesion to the endothelial walls is the 
expressions of CXCR4 and CXCR7 receptors. Therefore, trials using cancer cells expressing 
CXCR4 (231-CXCR4) and CXCR7 (231-CXCR7) were also used to study their effects. 
Results showed that all three trials showed increased adhesion with faster flow rates. A 
significantly larger adhesive ability was also noted for trials containing CXCL12 in the 
HDMEC than trials without it. However, the ratio of treated cells to untreated cells showed 
similar values for all three. Therefore, while CXCL-12 enhances adhesion, it is independent 
of CXCR4 and CXCR7.  To study the role HDMEC plays on adhesion, new trials were 
conducted in which the HDMEC monolayer was treated with CXCL12, which is known to 
up-regulate CXCR4, TNF-α, which is known to up-regulate both CXCR4 and CXCR7, and 
AMD3100 in combination with CXCL12, which inhibits binding for CXCL12-CXCR4, but 
not CXCL12-CXCR7. These were tested in the downstream channel to observe the effects 
(Fig. 11G). Results showed that inhibiting the CXCL12-CXCR4 connection led to the lowest 
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percentage of adhesion. This experiment showed not only a microfluidic device capable of 
replicating a microenvironment resembling breast cancer adhesion to the human vasculature, 
but also showed that disabling certain chemokine connections may prove to be an important 
step towards the regulation of metastasis. 
 
Fig. 11. Design of the device, showing A) a layer-by-layer layout of the two PDMS layers 
with a membrane in-between them.  B) A cross-sectional view of the device can be seen at the 
location where the channels overlap, showing the flow of medium with cultured cells. C) 
HDMEC cultivation shown by region (upstream, middle, downstream) through phase 
contrast imaging (scale bar at 800μm).  D) An actual photo of the device, with a quarter for 
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scale. E) Aerial view of the device, showing the locations of overlap, as well as the direction 
of flow. F) Interaction of HDMEC cells with flow from lower channel can be seen through 
fluorescent staining. Fluorescent dye was administered in the lower channels, showing 
interaction with the sections overlying the bottom channels, but not in the middle (scale bar 
at 800μm). G) Adhesion of MDA-MD-231, with TNF-α treated only at the downstream 
channel (scale bar at 200μm) [76]. 
 
Cancer migration to bone is another scenario that has been researched. Bersini et al. 
[8] created a microfluidic system to look at the interaction between breast cancer cells within 
a microenvironment used to represent bone structure. The device uses 3 microchannels with 
8 hydrogel regions within 4 hydrogel channels. Culture media flows through the 3 
microchannels, with HUVEC cells cultivated in the central channel. Cultivated hBM-MSC 
bone marrow cells within a collagen type 1 solution were injected into the 4 hydrogel 
channels structured with ECM. This produced an osteo-cell region within the hydrogel 
channel. After 3 days of cultivation, breast cancer cells (MDA-MB-231) were introduced to 
the system. Trials focused on observing the cross-talk between the osteo-cell regions and the 
breast cancer cells. Specifically, the interactions of CXCL5, a chemokine derived from the 
hBM-MSC, and the CXCR2 receptor from MDA-MB-231.  Results showed that in 
comparison to a gel only region (38%), the osteo-cell hydrogel region contained more 
transmigrated cancer cells (78%). These cancer cells were also able to penetrate deeper into 
the osteo-cell microenvironment. Additionally, the transmigrated cells showed signs of 
proliferation within the osteo-cell region. These proliferated cancer cells formed in clumps 
ranging from 4-60 cells. These results were successful in showing a functional cancer-bone 
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cross-talk environment. Additionally, their environment promoted cancer cell transmigration, 
both in quantity and depth. Taking this into account, along with the observations of cancer 
cell metastasis within the osteo-cell region after transmigration, it is clear that the osteo-cell 
region provided a suitable environment for cancer cells. 
A design focused on the extravasation of cancer cells through an endothelial barrier 
was developed by Jeon et al. [77]. Similar to the previous design, this design contained three 
microfluidic channels with hydrogel compartments separating each channel.  These hydrogel 
compartments contained an ECM structure. Human microvascular endothelial cells 
(hMVECs) were seeded within the central channel and cultured in the device. The cell line 
MDA-MB-231 was used to represent the tumor cells. These cells were also introduced into 
the central challenge after a confluent monolayer of hMVEC cells were formed. Results 
showed a successful extravasation of tumor cells through the endothelial barrier, with signs 
of proliferation in the ECM gel. Additionally, it was found that the number of extravasated 
cells stagnated after the first day, in agreement with in vivo studies. 
 
2.3.7.5 Multiple Organs 
As briefly discussed earlier in this paper, organ-on-a-chip technology can be applied 
to a system of multiple organs, and sometimes dubbed “human-on-a-chip,” depending on 
how large of a portion of the human body the device represents.  This has been the focal 
point to some research topics [78].  Multiple organs-on-a-chip provide their own challenges 
mainly due to their complexity.  Organ-organ interactions themselves add another layer of 
complexity to the system [79]. 
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Scaling from a multiple organ-on-a-chip in order to apply to in vivo humans is a 
challenge in and of itself [80].  Before body-on-a-chip systems can be implemented, 
consideration of the scaling effect between these micro-representations of organs with their 
actual in vivo counterparts must be done. Wikswo et al. [80a] broke this idea down into several 
groups.  
First, an allometric scaling can be done to represent organs. Because humans scale 
allometrically, scaling differences between interconnected organ-on-a-chip systems provide 
an especially difficult challenge for researchers. Not only would scaling involve 
considerations for the mass allometrics of the organs, but properties such as blood circulation 
and pulse would also be affected by scaling. Another consideration would be the aspects and 
properties of organs that are independent of size, which may fail or become dysfunctional 
when scaled. 
The second approach towards dealing with scaling is considering the human-on-a-
chip as only a portion of the human body, dubbed “histological sections”. In this respect, 
scaling considerations become unnecessary. The design can be such that the designed section 
of the organ only needs to perform the physiological duties associated with that section, 
eliminating some of the complexity of mimicking in vivo organs. Issues can arise when 
combining these sections due to either misrepresenting the organ-organ interactions by not 
considering the effects of a missing section of one of the organs or by not accounting for the 
scales of the sections relative to each other. 
The third approach is to scale with consideration to organ functions. In other words, 
the preservation of the important organ functions is paramount when scaling in this respect. 
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The drawback for this approach is that it may oversimplify the design to the point where 
various results aren’t translatable. 
Work done by Zhang et al. [81], combined a multi-channel three dimensional cell 
culture system with compartments for different cells. Four different organs were tested in this 
system: C3A cells (liver), A549 cells (lung), HK-2 cells (kidney) and HPA cells (fat). All 
organs were connected and a “common medium” (CM) was created to keep the functions of 
each individual cell line. Results showed that all but the HK-2 cells were able to function at 
expected levels, with HK-2 functionality decreased 10%. Despite this shortcoming, the 
medium was deemed suitable for the experiment.  The cells were connected to a reservoir 
containing the medium, with connections to an inlet directly attached to each cell group. The 
effects of TGF-β1 were tested in the multi-chip. Results showed that it did have the 
capabilities of promoting cell growth in A549, HK-2, and HPA cells. However, it also 
resulted in a much lower viability of C3A cells. To counteract this effect, gelatin 
microspheres were fabricated, with the ability to control the release of TGF-β1 so that it is 
only delivered in the A549 cell group. The results showed that A549 cells were indeed 
stimulated without adverse effects to any other cells. This experiment is capable of testing 
the multi-organ implications from drug toxicity testing. 
A microscale cell culture analog (µCCA) based on a pharmacokinetic-
pharmacodynamic (PK-PD) mathematical model has also been explored as a means to create 
a “body-on-a-chip” [82].  This model has the potential to be able to mathematically predict and 
map out the pharmacological effects of a drug. Sung et al. [83] tested the capabilities of PK-
PD modeling with a multi-organ chip device designed to test drug toxicity. Three different 
cell lines were cultivated in separate cell culture chambers: HepG2/C3A (liver), HCT-116 
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(tumor), and Kasumi-1 (marrow). A reservoir containing suitable medium is fed into the 
three cell culture chambers. Flow was induced through a rocking motion, allowing gravity to 
control the flow rate. This devices changes course every 3 minutes, ensuring that good 
viability is maintained throughout the device. Layout of the device can be seen in Fig. 12. 
Trials were done in which 5-fluorouracil (5-FU), an anti-cancer drug, was introduced into the 
medium. Different trials were done at varying concentrations. Both PK-PD modeling and 
experimental testing were done to observe the results.  Results from experimental data show 
similar trends. Further trials were conducted using both 5-FU and uracil, which is known as a 
modulator of 5-FU. Results showed a decline in viability between all three cell groups. 
Through this experiment, PK-PD modeling and microfluidic multi-organ functionality were 
combined to test the functionality when introduced to a drug test. The results obtained from 
this experiment are promising, and may lead to future studies in this area.  
 
Fig. 12. Layout of the device, showing A) the layer-by-layer design, and B) the image of the 
assembled device, with a quarter for scale [83]. 
A sample design of a body-on-a-chip was designed using chips discussed in this 
paper (Fig. 13.). When inter-connecting organ-on-a-chips, it is vital to recognize which 
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organs must interact with others, and conversely, which organs must be separated from 
others. The medium introduced must be able to interact with the various cells without 
harming them. 
 
Fig. 13. Sample construction of a body-on-a-chip using microfluidic chips discussed in this 
paper.  Drug testing would begin at the lung [26] or gut [40], with the liver [16] only accessible 
through the gut. From there, the flow would travel in the blood, reaching the kidney [50], 
heart [58], bone marrow [67], brain [69], spleen [70], and vasculature [66].  
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2.4 Summary Table 
The table categorizes each work based on the type of organ, type of testing, details of the 
design and experiments, and the cells used. 
 
Table 1. Summary of organ-on-a-chip devices listed in order of type of organ. 
Orga
n 
Type of 
testing 
Details Cultured cells in 
device 
Author 
          
Liver Toxicity
/ Drug 
Testing 
Created 3D HepaTox Chip for 
hepatotoxicity testing 
Harvested rat 
hepatocytes 
Toh et al. 
[13] 
    Encapsulated hepatocytes in 3D 
microtissues to study the 
interactions of drugs 
Harvested rat 
hepatocytes 
Li et al. 
[12a] 
    MODS platform for hepatotoxicity 
screening 
HepG2 and NIH-3T3 Au et al. 
[17b] 
    Characterizing the toxicity of several 
compounds using liver co-culture 
and SMART-scale analysis 
HepG2/C3A and 
MDCK 
Shintu et 
al. [20] 
    Drug metabolism using liver and 
intestinal slices 
Harvested rat liver 
and intestinal slices 
van 
Midwoud 
[22] 
    Testing the effects of ethanol-
induced toxicity on liver slices 
Harvested rat liver 
slices 
Hattersle
y et al. [21] 
  Functio
nal 
analysis 
Creating model with bile canaliculi 
formation 
Harvested rat 
hepatocytes 
Nakao et 
al. [14] 
    Incorperated biosensors for pH 
monitoring in chip  
HepG2 Schober 
et al. [15] 
    The kinetic reactions representing 
metabolism, measured and 
compared with mathematical model  
Harvested rat liver 
microsomes 
Lee et al. 
[16] 
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Table 1. continued 
 
    Liver sinusoid pattern assembly 
through use of dielectrophoresis 
Primary human 
hepatocytes and 
endothelial cells 
Schütte 
et al. [18] 
    Mimicking of the acinus function in 
the liver 
Hepatocytes and 
nonparenchymal 
cells 
Bhushan 
et al. [17a] 
    Liver and skin co-culture used to test 
long-term functionality under 
HHSteC and skin 
biopsies 
Wagner 
et al. [19] 
    Created IIDMP to evaluate dynamic 
organ-organ interactions of the liver 
and intestine 
HepG2/C3A and 
Caco-2 TC7 
Bricks et 
al. [23] 
Lung Toxicity
/ Drug 
Testing 
Modeling disease functions through 
a chip undergoing cyclic mechanical 
strain 
Human alveolar 
epithelial/microvasc
ular endothelial 
cells 
Huh et al. 
[27] 
    Cellular response and resistance to 
anticancer drug testing 
SK-MES-1 Siyan et 
al. [32] 
    Modeling the nasal epithelium for 
formaldehyde toxicity testing 
NIH/3T3 and 
hNESPC 
Wang et 
al. [34] 
  Functio
nal 
analysis 
Representing pulmonary diseases 
through propogating liquid plugs 
SAEC Huh et al. 
[25] 
    Analysis of the role of surfactants in 
liquid plug injury 
A549, ATCC Tavana et 
al. [26] 
    Testing the transport properties 
with physiological "breathing" chip 
design 
Human alveolar 
epithelial/microvasc
ular endothelial 
cells 
Huh et al. 
[7] 
    Observing cellular injury through 
both solid and fluid mechanical 
stress 
A549, AEC Douville 
et al. [28] 
    Producing suitable levels of gas 
transfer for artificial lung 
applications 
N/A Kniazeva 
et al. [29] 
    Gaseous exchange in vascular 
network through creation of free-
standing membranes 
N/A Sreenivas
an et al. 
[31] 
    Optimizing flow and gaseous 
exchange through use of a vascular 
scaffold 
N/A Hoganson 
et al. [30] 
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Table 1. continued 
 
 
Intest
ine 
Toxicity
/ Drug 
Testing 
μCCA model to study GI tract and 
predict drug toxicity 
Caco-2 and 
HepG2/C3A 
Mahler et 
al. [36] 
    Testing drug permeability in the 
intestinal epithelial cell membrane 
through use of microhole trapping 
Caco-2 Yeon et 
al. [44] 
  Functio
nal 
analysis 
Use of hydrogels as a platform for 
cultivated cells in a GI tract design 
Caco-2 Sung et 
al. [38] 
    Functional model for potential 
integration in a body-on-a-chip 
design 
Caco-2 Esch et al. 
[37a] 
    Compound analysis through pH 
control with respect to GI tract 
activity 
N/A Morimot
o et al. 
[37b] 
    Mimicking the function of mucus 
secretion in the stomach 
N/A Li et al. 
[37c] 
    Characteristing flow and transport 
properties of the instines using a villi 
scaffold 
Caco-2 Kim et al. 
[37d] 
    Modeling lipid digestion in various 
gastrointestinal conditions 
N/A Marze et 
al. [37e] 
    Analyzing signals through bacteria-
cell interaction in GI tract 
HeLa S3 Kim et al. 
[39] 
    Utilizing mechanical stress and 
microbes in a gut-on-a-chip 
Caco-2 Kim et al. 
[40] 
    Generation of 3D intestinal villi 
through introduction of mechanical 
stress 
Caco-2 Kim et al. 
[41] 
    Use of polarized cells to create 
microenvironment suited for long-
term perfusion 
Caco-2 Kimura et 
al. [42] 
    Testing the permeation abilities and 
intestinal absorption through 
microfluidics 
Caco-2 Imura et 
al. [43] 
Kidne
y 
Toxicity
/ Drug 
Testing 
Testing the effects of drugs on the 
profliferation of a dynamic kidney 
microfluidic chip  
MDCK Baudoin 
et al. [47] 
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Table 1. continued 
 
    Exposure to fluid flow to create 
functionality and measure 
nephrotoxicity activity 
Human kidney 
proximal tubular 
epithelial cells 
Jang et al. 
[50] 
  Functio
nal 
analysis 
Using optical vortices to enhance 
the functions of a blood cleaner-on-
a-chip 
N/A Suwanpa
yak et al. 
[46a] 
    Fabricating a nanofiber membrane 
for filtration in a microfluidic design 
N/A Lee et al. 
[46b] 
    Analyzing the gene and protein 
expression in MDCK cells 
MDCK Snouber 
et al. [46c] 
    Role of patterned membrane in 
renal chip function 
HK-2 and RPTEC Frohlich 
et al. [46d] 
    Use of adipose-derived stem cells in 
enhacing renal properties and 
functions 
MDCK and CG-ASC Huang et 
al. [46e] 
    Utilization of fluid shear stress to 
enhance renal functions 
IMCD Jang et al. 
[48] 
    Collecting duct-on-a-chip to 
investigate the effects of changes 
within a renal environment 
IMCD Jang et al. 
[49] 
    MTMD capable of utilizing fluid 
shear stress and topographical 
patterns 
HK-2 Frohlich 
et al. [51] 
    Using TEER measurements to 
analyze a working kidney bioreactor 
under fluid shear stress conditions 
HREC and MDCK Ferrell et 
al. [52] 
    Analyzing filtration for mass transfer 
capabilities modeling a glomerular 
unit 
N/A Ould-Dris 
et al. [53] 
    Investigation of the properties of 
mass transfer and drug transport in 
MDCK cells 
MDCK Ramello 
et al. [54] 
Heart Functio
nal 
analysis 
Studying the contraction of a single 
cardiomyocyte 
Harvested rabbit 
heart tissue 
Li et al. 
[57a] 
    Measurements conducted through 
electrode array analyzing a 
functioning cardiomyocyte 
Harvested rabbit 
ventricular 
myocytes 
Cheng et 
al. [57b] 
    Effects of myocardial injury in a 
micropillar array environment 
H9C2 Ren et al. 
[57c] 
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Table 1. continued 
 
    Reconstituting Barth's syndrome 
through a functional heart-on-a-chip 
iPSC-CM Wang et 
al. [57d] 
    Studying the functions of skeletal 
myoblasts for myocardial injury 
H9C2 and L6 
myoblasts 
He et al. 
[57e] 
    Replicating physical loading in the 
left ventricle through a μCCCM 
H9C2 Giridhara
n et al. [58] 
    Fabrication of micro spherical pump 
made from cardiomyocytes 
Rat cardiomyocyte 
cells 
Tanaka et 
al. [60] 
    TSM sensor for acoustic wave 
analysis of cardiomyocyte 
contractions 
Rat ventricular 
cardiomyocytes 
Li et al. 
[61] 
    SVF method for organ tissue analysis Chick heart Owaki et 
al. [62] 
Vasc
ulatu
re 
Functio
nal 
analysis 
Implantable microfluidic device for 
formation of vasculature 
hEPC Kim et al. 
[64a] 
    Studying the effects of the 
architecture in the vasculature 
through ECM distribution 
HUVEC Baker et 
al. [64b] 
    Creation of vasculature network 
through material fracture 
N/A Huang et 
al. [64c] 
    Establishing vasculature transport 
for use in multi-organ applciations 
HDMEC Schimek 
et al. [64d] 
    Creating diffusive vasculature 
network from hydrogel 
pHUVEC Mu et al. 
[64e] 
    Using TEMS to replicate vasculature 
environment 
HUVEC, hCMEC/D3, 
BT-474/PC3 
Tourovsk
aia et al. 
[64f] 
    Bifurcating microchannel 
vasculature network with circular 
cross-sections 
HUVEC Borenstei
n et al. [65] 
    Effects of shear stress, monocyte-EC 
adhesion, and monocyte 
transmigration on a vasculature 
system 
PAEC, RAW264.7, 
THP-1 
Srigunapa
lan et al. 
[66] 
Bone 
Marr
ow 
Toxicity
/ Drug 
Testing 
Radiation-induced toxicity effects on 
a bone marrow-on-a-chip 
hematopoietic and 
adipocyte cells 
Torisawa 
et al. [67] 
Canc
er/Tu
mor 
Toxicity
/ Drug 
Testing 
Studying chemotherapy resistance 
using a lung cancer microfluidic 
model 
SPCA1 Zhang et 
al. [71a] 
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Table 1. continued 
 
    Effects of anticancer drugs on lung 
and stromal cells 
SPCA1 and HFL1 Xu et al. 
[71b] 
    Analysis of CTCs in multiple lung 
cancer cell lines 
A459, SK-MES-1, 
and H446 
Huang et 
al. [71c] 
    Analysis of chemotherapy resistance 
and inhibitors for lung cancer model 
SPCA1 Meng et 
al. [71d] 
    Observing the effects of various 
drugs on breast cancer cells through 
a droplet microfluidic device 
MDC-MB-231 Gong et 
al. [72d] 
  Functio
nal 
analysis 
MMICH platform for diagnosis of 
breast cancer  
AU-565, SK-BR-3, 
HCC70, and MCF-7 
Kim et al. 
[72a] 
    Detection of breast cancer 
recurrence using PDMAEMA 
N/A Chen et 
al. [72b] 
    Modeling the transition from DCIS 
to IDC for breast cancer analysis 
MCF-DCIS and HMF Sung et 
al. [72c] 
    CTC capture and analysis for 
prostate cancer in a GEDI device 
U937, PC-3, LNCaP, 
and C4-2 
Kirby et 
al. [73a] 
    EIS biosensor for prostate cancer 
screening 
N/A Chiriacò 
et al [73b] 
    Separation of prostate cancer cells 
from white blood cells using 
acoustophoresis 
DU145, PC3, LNCaP Augustss
on et al. 
[73c] 
    Recreating prostate cancer 
microenvironment using fluid shear 
stress 
PC-3 Liu et al. 
[73d] 
    Analysis of CTC in pancreatic cancer 
cell line 
MCF-7, Hs578T, and 
SW620 
Kamande 
et al. [74] 
    Using an MCS for characterization of 
brain cancer cells 
A172, 1321N1, 
L0329, and L0367 
Khan et 
al. [75] 
    Replicating the functionalities of 
breast cancer cells ina vasculature 
system 
HDMEC and MDA-
MB-231 
Song et 
al. [76] 
    Observing the effects of breast 
cancer cells within a bone structure 
microenvironment 
HUVEC, hBM-MSC, 
and MDA-MB-231 
Bersini et 
al. [8] 
    Extravasation of cancer cells 
through an endothelial barrier 
hMVEC and MDA-
MB-231 
Jeon et 
al. [77] 
Brain Toxicity
/ Drug 
Testing 
Drug permeability testing through 
the BBB 
HUVEC Yeon et 
al. [68c] 
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Table 1. continued 
 
  Functio
nal 
analysis 
Creation and utilization of a SyM-
BBB to monitor tight junctions and 
permeability 
RBE4 Prabhaka
rpandian 
et al. [68a] 
    Analysis of μBBB device to replicate 
permeability and cell characteristics 
b.END3 and C8D1A Booth et 
al. [68b] 
    Integrating collagen into BBB model 
capable of permeability and shear 
stress analysis 
Endothelial cell, 
pericyte, and 
astroglia 
Shibata 
et al. [68d] 
    Use of TEER measurements to test 
functionality of BBB-on-a-chip 
hCMEC/D3 Griep et 
al. [69] 
Splee
n 
Functio
nal 
analysis 
Fast-flow/Slow-flow device for 
testing deformability of RBC in the 
spleen model 
N/A Rigat-
Brugarola
s et al. [70] 
Multi
ple 
Orga
ns 
Toxicity
/ Drug 
Testing 
Multi-cell design for monitoring 
glucose concentration in the 
presense of various metabolites 
Omental adipose 
tissue, HUVEC, and 
HepG2 
Iori et al. 
[78b] 
    Monitoring the multi-organ 
implications from drug toxicity 
testing 
C3A, A549, HK-2, 
and HPA 
Zhang et 
al. [81] 
    Testing toxicity effects on multi-cell 
device complete with a hydrogel 
structural microenvironment 
HCT-116, 
GepG2/C3A, and 
Kasumi-1 
Sung et 
al. [82b] 
    µCCA based on PK-PD model to 
predict pharmacological effects of a 
drug 
HCT-116, 
GepG2/C3A, and 
Kasumi-1 
Sung et 
al. [83] 
  Functio
nal 
analysis 
Hanging drop technique for 
fabrication of multi-cell device 
HCT-116 eGFP and 
rLiMT 
Frey et al. 
[78a] 
 
2.5 Conclusions 
Organ-on-a-chip systems are still a relatively new area of research, but have shown the 
potential to produce successful results with few caveats.  For this reason, it is important to be 
able to expand the horizon with these systems and explore new ideas within this area. In a 
broader sense, this research promotes the exploration of cheap, reliable alternatives to other 
forms of drug testing.  Organ-on-a-chip designs have the potential to be mass produced and 
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use few amounts of materials.  This would have the potential of being used universally, 
including underdeveloped countries.  
However, there are still steps needed to be taken in order to reach this level of 
reliability. While most tests have shown the ability to mimic organ functions and reactions, 
these are still not at the level to be a successful alternative to in vivo studies. Issues with 
inducing all the potential mechanical forces, achieving respectable permeation rates, 
producing efficient flow through polymer compartments, and recreating the microscale 
ecosystem of organisms, cells, bacteria that are relevant to the function of the organs, are 
considerations that require continued improvement. Additionally, single organ studies 
neglect to consider the implications that other organs within the same flow would have on 
that organ. Body-on-a-chip studies show great promise in this respect, but issues with 
components positively effecting one culture and negatively affecting another must be 
corrected. Methods like creating a gelatin microsphere for time-release drugs or providing a 
common medium to the system have shown promise as a way to integrate multiple cell 
cultures. 
Through this review, individual organs are analyzed, with attention brought to their 
design, materials, objectives, and results. Additionally, multi-organ systems are discussed, 
with a sample model of a “body-on-a-chip” created using designs mentioned in this paper. 
While it may not be as straightforward as simply connecting the designs with one another, 
this construction of a body-on-a-chip shows that the ability to create a successful body-on-a-
chip is not inconceivable with successful designs of individual organs. 
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CHAPTER 3 
 DESIGN AND FABRICATION 
 
3.1 Design Considerations 
 In determining the size and geometry of the design, there are two important 
considerations that will greatly affect the ability of the chip to diffuse properly: cross-
sectional geometry and flow path. 
 In looking at the cross-sectional geometry, many different shapes were considered. 
Sharp et al.4 looked at how the cross-sectional geometry would affect the Reynolds number 
and velocity of the flow. A summary of the results can be seen in Table 1. For each given 
cross-sectional geometry, the Reynolds number (given in terms of the friction factor) and the 
ratio of maximum fluid velocity to bulk velocity were analyzed, where f is the friction factor, 
Re is the Reynolds number, umax is the maximum fluid velocity, and uB is the bulk velocity 
As part of the analysis of fully developed flow through these geometries, Sharp et al. 
concluded that the geometry plays a relatively small role in controlling the Reynolds number 
and velocity through the microchannels. 
 However, the flow velocity and Reynolds number aren’t the only relevant parameters 
that will determine the channel design. Another parameter that needs to be considered when 
designing the channel is the particle transport properties.  
 In considering particle transport, it is important to bring the particles close to the area 
of interaction. For the organ-on-a-chip, this would be the membrane that is positioned 
between the channels. 
A rectangular cross-section was chosen for two reasons. First, in inertial focusing 
80 
 
 
Table 2. Various cross-sectional geometries and their resulting parameters.4  
 
 
 
applications, laminar flow in rectangular cross-sections typically group particles in two 
distinct pockets located close to the walls of the longer sides, due to both the Reynolds 
number and the particle confinement ratio.5  Bringing particles closer to the wall adjacent to 
the membrane will provide the system with a greater percentage of diffusion from one 
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channel to another. A visual representation of this can be seen in Figure 14. Second, the 
simplicity of a rectangular channel allows for straight walls, containing no bends, which can 
be easily manufactured by a variety of methods. 
 
Figure 14. The effect of cross-sectional geometry in particle distribution in square and 
rectangular ducts with 𝑎𝑝/𝐷ℎ ≥ 0.07, where 𝑎𝑝 is the diameter of the particle and 𝐷ℎ is the 
hydraulic diameter of the microchannel. The particle distribution is shown as the Reynolds 
number increases from 5 (bottom) to 20 (middle) to 100 (top).5 
 
 While the Reynolds number and particle confinement ratio are responsible for particle 
distribution in straight channels, it is also important to consider whether curvature in the flow 
path would be beneficial for the design. This property is controlled by the Dean flow. Martel 
et al.6 analyzed the role of the Dean flow in a rectangular cross-sectional duct. The studies 
looked at not only how the channel curvature controlled the particle distribution, but also 
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how the size of the particles were affected by the degree of curvature. The results can be seen 
in Figure 15.  
 
 
Figure 15. The effect of curvature on particles of various sizes in a duct with a rectangular 
cross-section. The particles have a particle confinement ratio of: λBlue = 0.066,  λGreen = 0.149, 
and λRed = 0.225. The curvature ratio is displayed (δ) for 4 different curvatures (a-d). The 
Reynolds number is given as Rec = 419.
6  
 
From this, it is clear that curvature along the lateral position will not be of benefit to 
this project, and curvature along the vertical position would prove to be too complex from a 
manufacturing standpoint. Therefore, in the area of diffusive interaction, a straight channel 
will be the most beneficial. 
From these considerations, the channel layout was created. Figure 16. shows a 
diagram displaying this layout. The inlets and outlets were designed such that they would be 
angled away from the other channel, therefore giving sufficient space to allow for connective 
tubing to be attached. Dimension sizes were chosen to be physiologically similar to its in vivo 
counterparts. 
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Figure 16. Channel layout of the placenta-on-a-chip, displaying an (a) aerial view of the 
channels and a (b) cross-sectional view of the overlapping midsection of the channels. In this 
design, red corresponds to the fetal stream and blue corresponds to the maternal stream. The 
green area represents the nanoporous membrane separating the channels. 
 
3.2 PMMA fabrication 
Initially, Polymethyl Methacrylate (PMMA) was chosen to be the material used for 
constructing the layers containing the microchannels, due to the fact that it is biocompatible, 
allowing it to be used in cell culture applications, and clear, allowing the interaction sight 
located between the layers to be seen through a microscope.  
The process of making the channels on PMMA consisted of using a micromilling 
technique. Modelling software (SolidWorks, USA) was first used to design the prototype 
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channel layout. Once the layout was configured, the spatial coordinates were implemented 
into a G-code, which was able to carve out the channel path with the dimensions specified 
earlier. 
 
3.3 Soft lithography 
The master mold was created using a soft lithography technique on a silicon wafer 
(Silicon Sense, Boise, ID). In this technique, the wafer was initially cleaned and placed into a 
plasma cleaner (Femto Science, South Korea) for 5 minutes. Then, the wafer was spin-coated 
with SU-8 50 negative photoresist (MicroChem, USA) to achieve a film thickness of 100 
µm. A two step soft bake was then applied to the wafer; 10 minutes at 65 °C followed by 30 
minutes at 95 °C. The wafer is then exposed to UV radiation from a photolithography 
machine (Kaon Tech, South Korea). The SU-8 is designed to be highly sensitive in this 
specific range of radiation (350-400 nm) and any direct UV exposure leads to cross-linking 
of the material. Therefore, a mask containing a clear layout of the channels was place over 
the wafer so that the channel layout becomes the only thing exposed to UV directly. An 
exposure energy of roughly 480 mJ/cm2 was then applied to the chip. A two step post 
exposure bake (PEB) was then applied to the wafer afterwards; 1 minute at 65 °C followed 
by 10 minutes at 95 °C. Afterwards, the wafer was immersed in a SU-8 Developer solution 
(MicroChem, USA). At this stage, the SU-8 that was not cross-linked from UV exposure is 
dissolved, leaving only the negative of the channel layout. Once the SU-8 is properly 
dissolved, the wafer is then rinsed and dried. 
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3.4 PDMS fabrication 
PDMS was used as the material of the layers containing microfluidic channels. 
PDMS was created by mixing prepolymer (Dow Corning, USA) and curing agent (Dow 
Corning, USA) at a 10:1 w/w ratio. The silicon wafer master mold described previously was 
used as the template for the PDMS. The resulting height and width of the channels were 100 
µm and 400 µm, respectively. For the top layer, PDMS was poured into the master mold and 
sealed in a vacuum chamber for 20 minutes to release any trapped bubbles within the PDMS. 
Any additional bubbles on the surface were removed and the wafer was heated at 95 °C for 
30 minutes. Once solidified, the individual layers were removed from the mold and 1 mm 
inlet/outlet holes were punched out. For the bottom layer, PDMS was spin-coated onto the 
wafer at 300 rpm for 30 seconds, followed by 10 rpm for 10 seconds. Bubbles on the surface 
were removed and the wafer was heated at 95 °C for 10 minutes. Once the PDMS solidified, 
the layer was irreversibly bonded to a 25mm x 40mm microscope cover glass slide. This 
allowed the channels to be located close in proximity to the glass slide, making it easier to 
observe through an inverted microscope. 
 
3.5 Membrane/Vitrified Collagen 
A nanoporous (0.4 µm diameter pores) PETE membrane was placed between the two 
PDMS layers. The PETE membrane was obtained by cutting the membrane from a 
Transwell® well plate with membrane insert (Corning Incorporated, USA). 
 
In a process known as collagen vitrification, a collagen gel solution can be kept 
dormant in a dried state, and then reactivated and gellified again once it is wetted. The 
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collagen solution was composed of 11 mg/ml rat tail collagen 1 (BD Biosciences, USA), de-
ionized water, and Dulbecco’s Modified Eagle Medium (DMEM, HyClone, USA) 
supplemented with 10% fetal bovine serum (FBS) and 100 units/ml penicillin/streptomycin. 
When mixing, all components were kept on ice to prevent premature gelation. The solution 
consisted of equal parts DMEM and collagen/de-ionized water, with a final collagen 
concentration of 2.5 mg/ml. 
The collagen solution was prepared and allowed to dry on the membrane for 24 
hours. Once dried, the top and bottom layers of PDMS were treated in the plasma cleaner and 
the membrane was positioned over the midsection of the channels before bonding. 
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CHAPTER 4 
 CELL CULTURE 
 
4.1 Introduction 
This chapter will briefly go over the general process used for bringing up, 
maintaining, splitting, and refreezing cell lines in this project. Cell culture processes were in 
accordance to standard practices set by the original manufacturers7. 
 
4.2 Bringing up original cell lines 
Vials containing the original cell lines were kept in deep freeze in liquid nitrogen 
tanks (-200°C). Once ready, they were quickly thawed in a water bath until only a sliver of 
ice was left in the vial. While this process occurs, roughly 10ml of media is brought into a T-
75 flask and is kept in an incubator at 37°C and 5% CO2 for 20 minutes. Once the vial is 
ready, the contents are brought into the T-75 flask containing the pertinent media. From 
there, the flask in kept in the incubator. 
 
4.3 Maintaining cell lines 
 Cells in T-75 flasks are checked daily and refreshed with new media periodically. 
When new media is introduced into the flask, it is first warmed up in a water bath kept at 
37°C for 20 minutes before being brought into the flask. Discarded media is put into a waste 
conical tube and mixed with at least equal parts ethanol. This mixture is left for at least 24 
hours before being properly disposed. Once refreshed, the flask is placed back in the 
incubator. 
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4.4 Splitting cell lines 
 Splitting is the process in which cells are removed from their current flasks and 
brought into one or several new flasks. In this process, the original media is first disposed 
(using the same disposal processes as mentioned in the previous section). The wall of the 
flask containing cells is then rinsed using several ml of cell stripping agent (such as Trypsin). 
After rinsing, the cell stripping agent is immediately disposed. Next, 1ml of cell stripping 
agent is added into the flask, and is allowed to settle on the bottom of the flask (side 
containing cells). During this time, cells are slowly stripped away from the bottom of the 
flask and become suspended in the media. Once most of the cells are stripped from the flask 
wall, the contents of the flask are then collected in a 15ml conical tube. Additionally media is 
added to the tube in order for the liquid to be at exactly 10ml. Then, the tube is brought to a 
centrifuge (Gizmo Supply Electric Centrifuge 800-1, Gizmo Supply Co., U.S.) and balanced 
using another tube containing the same amount of liquid. The needed relative centrifugal 
force (RCF) and centrifugation time varies depending on the cell line. To convert between 
RCF and revolutions per minute (RPM), the following equation becomes important 
𝑅𝐶𝐹 = 11.18 × 𝑟 × (
𝑄
1000
)
2
 
where RCF is relative centrifugal force expressed as a factor of g, r is the radius from the 
center of the rotor to the end of the conical tube, and Q is the revolutions per minute. After 
centrifugation, the liquid solution is disposed and the leftover pellet of cells is resuspended in 
fresh media and brought into a new flask (or flasks). Additional media is then added to the 
flask until the desired amount is obtained. 
 
89 
 
 
4.5 Refreezing cell lines 
 Freezing down cells after sufficient splitting is a good way of maintaining a good 
supply of cells for long term research. When freezing, a freeze media must first be created. 
This is typically done using 10% DMSO along with 90% complete media. Cells are then 
stripped and centrifuged (as described previously), with the leftover pellet being resuspended 
in the new freeze media. After resuspension, roughly 1ml is introduced into each freezing 
vial. There is some flexibility in the amount of cells required for each vial, but a sufficient 
amount of cells are needed into to restart the vial once the time comes for thawing. Once the 
freezing vials are filled, they are stored in a -80°C freezer overnight, then brought down in a 
liquid nitrogen tank the following day. 
 
4.6 Controlling cell density 
Before introducing cells into the chip, it is important to be able to know the density of 
the cells within the media. To do this requires obtaining a pellet of cells, through the 
centrifugation processes mentioned in Section 4.4. Once a pellet is formed and the media 
solution is discarded, a small amount of fresh media is added (between 50-300µl depending 
on the size of the pellet). The cells are then resuspended in this media until the concentration 
is uniform. Next, 10µl of the cells are mixed with 40µl of Trypan Blue Stain (0.4%) (Gibco, 
U.S.). Then, 10µl of this new mixture is obtained and then introduced into a hemocytometer 
(LW Scientific, U.S.) and observed under a microscope. The purpose of the hemocytometer 
is to produce an easy-to-see grid of known size, so that a cell count can result in an estimate 
of the cell density. When looking through at a hemocytometer through a microscope, a grid 
of 25 squares (5 x 5), each containing their own 25 squares, can be seen in the center.  
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 To find the cell density, the number of visible cells in this grid must first be counted. 
To account for the 1:5 ratio of dilution from adding Trypan Blue, the number of counted cells 
must be multiplied by 5. To scale it into terms of cells per ml, that count number must then 
be multiplied by 104. For example, if a cell count of 40 was observed within the 
hemocytometer grid, the resulting cell density would be considered 2 million cells/ml. 
 In order to change the density to a desirable value, the following equation must be 
considered: 
𝑉1
𝑉2
=
𝜌1
𝜌2
 
where 𝑉1 and 𝜌1 are the initial volume of the cell solution and initial cell density, 
respectively, and 𝑉2 is the volume needed to obtain the desired cell density, 𝜌2. When 
looking to change the cell density, it is important to note that 𝑉2 must be greater than 𝑉1. That 
is, when changing the cell density, it is far easier to add more media to dilute the solution 
than to take media away from the solution. For example, if the original cell density was 2 
million/ml and the initial volume of the solution was 300µl, and the desired cell density was 
5 million/ml, solving for 𝑉2 would yield a needed volume of 750µl. In other words, 450µl 
would need to be added to the solution. 
 
4.7 References 
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CHAPTER 5 
 PRELIMINARY TESTING OF THE DESIGN ON A LIVER-ON-A-CHIP PLATFORM 
 
5.1 Introduction 
In the human body, the liver is responsible for regulating protein and glucose intake, 
removing and breaking down toxins, and processing nutrients in the bloodstream. The liver is 
unique in that it is mostly composed of one type of cell. These cells are known as hepatocyte 
cells, and they play a large role in the functionality of the liver8. Understandably, when 
growing these cells in vitro, these cells show an affinity for clumping together. In designing 
an in vitro liver, researchers have utilized these unique characteristics when creating their 
respective liver-on-a-chip platforms9. 
This chapter outlines a supplemental project in which the placenta-on-a-chip channel 
layout designed from the previous chapter (using PDMS) was tested on a liver-on-a-chip 
platform. Both a healthy liver model and a model of the liver undergoing ethanol-induced 
toxicity were analyzed, in the hopes that this technology could map both ideal and non-ideal 
conditions. 
 
5.2 Cell Culture 
HUVECs were cultured in Endothelial Growth Medium (EGM-2 MV, Lonza). 
HepG2 cells were cultured in DMEM supplemented with 10% FBS and 100 units/ml 
penicillin/streptomycin. Both cell lines were kept in an incubator providing 37 °C and 5% 
CO2. 
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5.3 Cell Integration into Chip 
Before cell loading, the tubing and syringes were sterilized with 70% isopropyl 
alcohol, followed by 20 minutes of UV radiation. Once the device was set up, the cells were 
stripped from their Petri dishes and concentrated to their intended densities. The density of 
HUVECs was brought to 5 x 106 cells/ml and the density of HepG2 was brought to 1.5 x 106 
cells/ml. In order to make the HepG2 cells more physiologically representative, a fibrin gel 
was made in order to suspend the cells. The fibrin solution consisted of 20 mg of Fibrinogen 
from bovine plasma (Sigma-Aldrich, USA) mixed with 2 ml of phosphate buffered saline 
(PBS). The HepG2 was suspended in a fibrin gel solution at a volume ratio of 1:3, followed 
by 1 µl of Trombin. This mixture was then injected directly into the bottom channel and 
seeded at 1.5 x 106 cells/ml. This gave the cells a 3D environment more similar to the bulk of 
hepatocyte cells seen in vivo. The HUVEC cells were injected into the top channel and 
seeded at 5 x 106 cells/ml. Flow was introduced into the top channel containing HUVEC cells 
 
5.4 Construction of a liver-on-a-chip 
Twelve chips were designed; 6 were incubated for 4 hours and the other six were 
incubated for 6 hours after the introduction of cells. Among these groups of six, 4 were 
connected to the syringe pump and had continuous flow, while the other two remained static. 
Additionally, between the dynamic and static flow groups, each had one chip designed 
without a collagen coating on the membrane. Thus, the effects of different variables on the 
system could be observed. Figure 17. shows the layout of this design. 
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Figure 17. Experimental set-up for dynamic flow through chips under various conditions. 
Flow is introduced through the use of a syringe pump. From the syringe, the medium enters 
the chip through the HUVEC inlet hole, and exits through the outlet. The outlet flow is then 
delivered into a waste vial. Design allows for multiple chips to be handled simultaneously. 
 
As indicated by Figure 18., once the cells were injected into the channel, they 
showed good density and were seeded appropriately. 
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Figure 18. Image of cells after introduction into the chip. Note that the channel arriving from 
the upper left of the figure contains the smaller, oblong HUVEC cells, while the lower 
channel contains the bulkier and more sparely spaced HepG2 cells.  The channel width is set 
at 400 µm 
 
5.5 Maintenance of a liver-on-a-chip 
Maintenance proved to be a difficult task in this design. The small cross-section of 
the channel made even smaller flow rates detrimental to the cells. Initial flow rate was 60 
µl/hr. Results showed a massive decrease in the HUVEC cell population after 24 hours. The 
system was then adjusted to 6 µl/hr and run for 72 hours. 
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5.6 Introduction of ethanol-induced toxicity 
Once cells were maintaining in their dynamic state for 72 hours, ethanol at various 
concentrations was introduced into the chip. The ethanol concentrations were tested at 0 
mmol/l, 17.4 mmol/l, 52.1 mmol/l, and 104 mmol/l. This corresponds to a BAC of 0, 0.08, 
0.24, and 0.48 percent by volume, respectively. The ethanol was introduced in both the 4 and 
6 hour trials in chips that contained the collagen membrane and cells. Flow rates remained 
unchanged and the system was run for 24 hours. 
 
After 24 hours, a live/dead staining method was implemented, in which dead cells are 
stained in red and live cells are stained in green. The staining solution consisted of 2ml of 
PBS, 4µl of red-fluorescent ethidium homodimer 1 solution (EthD-1), 1µl of green-
fluorescent calcein-AM, (Sigma-Aldrich, USA), and 0.6 µl of Hoechst. 
 
Results were consistent with what was expected for the trial. Cells contained low 
viability once flow was induced. The cells that remained were pushed towards the wall and 
any viability that remained was killed off by the ethanol. Figure. 19. displays an example of 
one of the fluorescent images taken, showing minimal cell adherence. 
 
Future steps in testing the adherence capabilities as a function of adherence time and 
flow rate to improve overall viabilities can prove to be vital for ethanol trials, where 
degradation of cell viability is a concern. 
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Figure 19. DAPI image of cells. Cells display low viability and density. 
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CHAPTER 6 
 PLACENTA-ON-A-CHIP 
 
6.1 Introduction 
Organ-on-a-chip technology is a relatively new field in which the properties of 
microfluidics are utilized within a biomimetic cell culture model. They show promise as a 
novel platform in drug testing and toxicology applications due to several key advantages. 
Their large surface area-to-volume ratio ensure that diffusive forces dominate over bulk 
forces.  
This has led to a vast increase in popularity over the recent years, as researchers have 
found them to be a more appealing alternative to other drug testing methods. From this, 
researchers have split into subsects that focus on a specific organ, including the: lungs, liver, 
intestines, heart, vasculature, and many others. 
Contrary to this, however, research regarding a “placenta-on-a-chip” have been few 
and far between. Miura et al.10 created a placenta-on-a-chip with cells grown on both sides of 
a collagen vitrigel membrane. Results showed that it was capable of forming confluent cell 
layers and transcellular transport of compounds through the membrane. Recently, Lee et al.11 
created a placenta-on-a-chip using JEG-3 trophoblast cells as their epithelial cell layer. Their 
device had no membrane, but instead used a vitrified collagen to create the barrier separating 
their channels. Once the device was set up, they measured the glucose transfer capabilities of 
the device and monitored the cell growth and viability during dynamic trials. 
In the body, the placenta is responsible for nutrient, waste, and gas exchange between 
the mother and fetus, as well as providing other needs such as endocrine function and 
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important antibodies12. The placental barrier refers to the barrier that separates the maternal 
blood from the fetal blood. In humans, this barrier is composed of 3 main layers: the vascular 
endothelium, the extracellular matrix (ECM), and the trophoblast (epithelium). The layout of 
the placenta, with specific focus on the placental barrier, can be seen in Figure 20. 
The formation of this barrier starts with the recruiting of trophoblast cells from the 
uterus. These cells invade the intervillous space and attach to one another to form the 
chorionic villi. There are two types of trophoblasts prevalent in the placenta: cytotrophoblast 
and syncytiotrophoblast. The cytotrophoblasts are mononuclear and are responsible for 
breaking down ECM within the chorionic villi to make the space that will eventually be 
taken over by the umbilical blood vessels. After completing their function, they are capable 
of fusing together to form a syncytrotrophoblast layer. This lies in the outermost layer of the 
chorionic villi and is in contact with the maternal blood, therefore making it extremely 
important in nutrient/waste exchange applications. 
The middle layer of the barrier is composed of the extracellular matrix. This matrix is 
comprised of the “fluff” separating the endothelial and epithelial layers. The ECM provides 
the cell layers with support, separation, and crosstalk (either cell-cell or cell-ECM). 
As stated previously, once the chorionic villi are hollowed out from the 
cytotrophoblasts, the fetal blood vessels are able to work their way inside of them. Therefore, 
when considering the barrier between bloodstreams, the layer that will be in contact with the 
fetal blood is the vascular endothelium of these blood vessels. The vascular endothelium is 
responsible for controlling particle transfer through the membrane, controlling the blood 
pressure, and aiding in the repair of damaged tissue. 
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In this work, these three layers are approximated on a microfluidic organ-on-a-chip 
platform to create a “placenta-on-a-chip.’ Human umbilical vein endothelial cells are used to 
represent the vascular endothelium, BeWo choriocarcinoma cells are used to represent the 
trophoblast, and a type 1 collagen solution overlaying a nanoporous polyethylene 
terephthalate (PETE) membrane is used to represent the ECM. 
 
Figure 20. Development of the fetus through use of the placenta and the placental barrier. 
 
 
6.2 Materials and methods 
In determining the size and geometry of the design, there are two important 
considerations that will greatly affect the ability of the chip to diffuse properly: cross-
sectional geometry and flow path. 
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 In looking at the cross-sectional geometry, many different shapes were considered. 
Sharp et al.4 looked at how the cross-sectional geometry would affect the Reynolds number 
and velocity of the flow. For each given cross-sectional geometry, the Reynolds number 
(given in terms of the friction factor) and the ratio of maximum fluid velocity to bulk velocity 
were analyzed. As part of the analysis of fully developed flow through these geometries, 
Sharp et al. concluded that the geometry plays a relatively small role in controlling the 
Reynolds number and velocity through the microchannels. 
 However, the flow velocity and Reynolds number aren’t the only relevant parameters 
that will determine the channel design. Another parameter that needs to be considered when 
designing the channel is the particle transport properties.  
 In considering particle transport, it is important to bring the particles close to the area 
of interaction. For the organ-on-a-chip, this would be the membrane that is positioned 
between the channels. 
A rectangular cross-section was chosen for two reasons. First, in inertial focusing 
applications, laminar flow in rectangular cross-sections typically group particles in two 
distinct pockets located close to the walls of the longer sides, due to both the Reynolds 
number and the particle confinement ratio.5  Bringing particles closer to the wall adjacent to 
the membrane will provide the system with a greater percentage of diffusion from one 
channel to another. Second, the simplicity of a rectangular channel allows for straight walls, 
containing no bends, which can be easily manufactured by a variety of methods. 
 While the Reynolds number and particle confinement ratio are responsible for particle 
distribution in straight channels, it is also important to consider whether curvature in the flow 
path would be beneficial for the design. This property is controlled by the Dean flow. Martel 
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et al.6 analyzed the role of the Dean flow in a rectangular cross-sectional duct. The studies 
looked at not only how the channel curvature controlled the particle distribution, but also 
how the size of the particles were affected by the degree of curvature.  
From this, it is clear that curvature along the lateral position will not be of benefit to 
this project, and curvature along the vertical position would prove to be too complex from a 
manufacturing standpoint. Therefore, in the area of diffusive interaction, a straight channel 
will be the most beneficial. 
From these considerations, the channel layout was created. Figure 21. shows a 
diagram displaying this layout. The inlets and outlets were designed such that they would be 
angled away from the other channel, therefore giving sufficient space to allow for connective 
tubing to be attached. Dimension sizes were chosen to be physiologically similar to its in vivo 
counterparts. 
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Figure 21. Channel layout of the placenta-on-a-chip, displaying an (a) aerial view of the 
channels and a (b) cross-sectional view of the overlapping midsection of the channels. In this 
design, red corresponds to the fetal stream and blue corresponds to the maternal stream. The 
green area represents the nanoporous membrane separating the channels. 
 
Initially, Polymethyl Methacrylate (PMMA) was chosen to be the material used for 
constructing the layers containing the microchannels, due to the fact that it is biocompatible, 
allowing it to be used in cell culture applications, and clear, allowing the interaction sight 
located between the layers to be seen through a microscope.  
The process of making the channels on PMMA consisted of using a micromilling 
technique. Modelling software (SolidWorks, USA) was first used to design the prototype 
channel layout. Once the layout was configured, the spatial coordinates were implemented 
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into a G-code, which was able to carve out the channel path with the dimensions specified 
earlier. 
Due to issues with stress breaks from the mechanical sealing process involved with 
PMMA, a PDMS based design was considered and implemented. The master mold was 
created using a soft lithography technique on a silicon wafer (Silicon Sense, Boise, ID). In 
this technique, the wafer was initially cleaned and placed into a plasma cleaner (Femto 
Science, South Korea) for 5 minutes. Then, the wafer was spin-coated with SU-8 50 negative 
photoresist (MicroChem, USA) to achieve a film thickness of 100 µm. A two step soft bake 
was then applied to the wafer; 10 minutes at 65 °C followed by 30 minutes at 95 °C. The 
wafer is then exposed to UV radiation from a photolithography machine (Kaon Tech, South 
Korea). The SU-8 is designed to be highly sensitive in this specific range of radiation (350-
400 nm) and any direct UV exposure leads to cross-linking of the material. Therefore, a mask 
containing a clear layout of the channels was place over the wafer so that the channel layout 
becomes the only thing exposed to UV directly. An exposure energy of roughly 480 mJ/cm2 
was then applied to the chip. A two-step post exposure bake (PEB) was then applied to the 
wafer afterwards; 1 minute at 65 °C followed by 10 minutes at 95 °C. Afterwards, the wafer 
was immersed in a SU-8 Developer solution (MicroChem, USA). At this stage, the SU-8 that 
was not cross-linked from UV exposure is dissolved, leaving only the negative of the channel 
layout. Once the SU-8 is properly dissolved, the wafer is then rinsed and dried. 
PDMS was used as the material of the layers containing microfluidic channels. 
PDMS was created by mixing prepolymer (Dow Corning, USA) and curing agent (Dow 
Corning, USA) at a 10:1 w/w ratio. The silicon wafer master mold described previously was 
used as the template for the PDMS. The resulting height and width of the channels were 100 
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µm and 400 µm, respectively. For the top layer, PDMS was poured into the master mold and 
sealed in a vacuum chamber for 20 minutes to release any trapped bubbles within the PDMS. 
Any additional bubbles on the surface were removed and the wafer was heated at 95 °C for 
30 minutes. Once solidified, the individual layers were removed from the mold and 1 mm 
inlet/outlet holes were punched out. For the bottom layer, PDMS was spin-coated onto the 
wafer at 300 rpm for 30 seconds, followed by 10 rpm for 10 seconds. Bubbles on the surface 
were removed and the wafer was heated at 95 °C for 10 minutes. Once the PDMS solidified, 
the layer was irreversibly bonded to a 25mm x 40mm microscope cover glass slide. This 
allowed the channels to be located close in proximity to the glass slide, making it easier to 
observe through an inverted microscope. 
A nanoporous (0.4 µm diameter pores) PETE membrane was placed between the two 
PDMS layers. The PETE membrane was obtained by cutting the membrane from a 
Transwell® well plate with membrane insert (Corning Incorporated, USA). 
In a process known as collagen vitrification, a collagen gel solution can be kept 
dormant in a dried state, and then reactivated and gellified again once it is wetted. The 
collagen solution was composed of 11 mg/ml rat tail collagen 1 (BD Biosciences, USA), de-
ionized water, and Dulbecco’s Modified Eagle Medium (DMEM, HyClone, USA) 
supplemented with 10% fetal bovine serum (FBS) and 100 units/ml penicillin/streptomycin. 
When mixing, all components were kept on ice to prevent premature gelation. The solution 
consisted of equal parts DMEM and collagen/de-ionized water, with a final collagen 
concentration of 2.5 mg/ml. 
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The collagen solution was prepared and allowed to dry on the membrane for 24 
hours. Once dried, the top and bottom layers of PDMS were treated in the plasma cleaner and 
the membrane was positioned over the midsection of the channels before bonding. 
The HUVEC cells were chosen to represent the endothelial layer of the device, 
cultured in an EGM-2 media. The human trophoblast cell line BeWo was chosen to represent 
the epithelial layer. The media used for the BeWo cells was F-12K, supplemented with 10% 
FBS. 
 
6.3 Results and discussion 
After sterilization of the device through ethanol and UV radiation (as previously 
described), HUVEC cells were first injected into the top channel of the chip at a seeding 
density of 5x106 cell/ml. To give the cells sufficient adherence, the chips were brought into 
an incubator (37°C, 5% CO2) and left for 12 hours to allow for attachment to the membrane. 
After sufficient time was given, the BeWo cell line was injected into the bottom channel of 
the chip at a seeding density of 5x106 cell/ml. Before injection, HUVEC cells were stained 
with CellTrackerTM Green CMFDA fluorescent dye (Life Technologies, Eugene, OR) and 
BeWo cells were stained with CellTrackerTM Orange CMRA fluorescent dye (Life 
Technologies, Eugene, OR). Fluorescent and bright field images taken before media flow can 
be seen in Figure 22. A look through the different filters allows us to key in on the specific 
cells of interest. For the HUVECs, a green fluorescent protein (GFP) filter is used, and for 
the BeWo cell line, a red fluorescent protein (RFP) filter is used. The system was observed 
through an inverted microscope (Axio Observer Z1 Inverted Microscope, Zeiss, Oberkochen, 
Germany). 
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Figure 22. Injected HUVEC (green) and BeWo (red) cells before the start of the trial, seen 
through: A) GFP filter, B) RFP filter, C) Brightfield, and D) GFP + RFP + Brightfield. Scale 
bar is at 200 µm. 
 
Once the cells were attached on the membrane within the chip, constant media flow 
was administered to the chip via syringes containing the cell media positioned on a double 
syringe pump (Cole-Parmer, Veron Hills, IL). Silicon tubing (HelixMark, Carpinteria, CA) 
with an inner diameter of 0.04 inches and outer diameter of 0.085 inches was used to connect 
the syringes to the inlets of the chip. Tubing was also connected to the outputs of the chip, 
which directed the media out of the chip to be collected, either as waste or for further 
analysis. The flow rate used for both channels in this system was 6 µl/hr. 
108 
 
 
 Long-term maintenance studies were performed on the chips once it was shown that 
the cells were able to adhere to the membrane and get nourishment from the media flow. The 
system was allowed to flow for 5 days. Afterwards, the system was checked under the same 
filters. Figure 23 shows the resulting images. 
 
 
Figure 23. Injected HUVEC (green) and BeWo (red) cells after 5 days of flow, seen through: 
A) GFP filter, B) RFP filter, C) Brightfield, and D) GFP + RFP + Brightfield. Scale bar is at 
200 µm. 
 
 
6.4 Conclusion 
 This technique shows how these pertinent cell lines can be introduced into a 
microfluidic design in order to create a biomimetic microsystem resembling the placenta. 
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Starting with the basic microfluidic phenomena that control particle density and dispersion, a 
model was designed the exploit these phenomena in order to create a drug testing platform 
resembling the placenta. Using this platform, cells were chosen based on their physiological 
traits and were successfully introduced into the device. This device was then able to be 
monitored for a significantly long term. 
 Cells shown after long term maintenance showed some migration, specifically 
towards the walls of the channels. This may be due to insufficient adherence of the cells or 
due to the strength of the flow in the channels. The decrease in cell density would suggest the 
latter, however, cells shown in Figure 22 display weak structural integrity that would suggest 
that they aren’t firmly attached to the membrane. These aspects can be further inspected to 
improve the functionality of the device. 
With the successful integration of cells into the microfluidic device, more avenues for 
analysis can be considered. One aspect to consider is the measurement of markers specific to 
the placenta. Protein-expressing markers provide a good indication of how well the system is 
operating and how similar it is to the in vivo environment. For example, E-cadherin, which is 
known for its role in cell-cell adhesion and epithelial cell signaling, can be found in the 
placenta at distinctly higher levels in vivo than in vitro. Additionally, an analysis of the 
impact of various flow rates and cell adhesion times can also be considered.  
Additionally, more studies can be done looking at the transepithelial electrical 
resistance (TEER) measurement. The TEER measurements prove useful in analyzing the 
confluency of the cell layer. 
Another area worth considering for future study is the role of ethanol-induced toxicity 
for the placenta-on-a-chip. Like the liver-on-a-chip discussed earlier, ethanol contained 
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within the maternal media stream can be representative of the blood alcohol content seen in 
cases involving fetal alcohol spectrum disorder. This could prove a useful tool in not only 
being able to use the placenta-on-a-chip in a healthy and functioning placenta, but also in 
mapping non-ideal scenarios. 
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CHAPTER 7 
CONCLUSION 
 
7.1 Conclusion 
In this design, a successful integration of cells into these organ-on-a-chip devices 
show the potential for 3D microfluidic devices to be used in drug testing and toxicology 
applications. Using a soft lithography method, a master mold was created and used to make 
PDMS layers that contained microchannels. Between the layers contained a PETE membrane 
with collagen acting as the extracellular matrix (ECM). As such, this model represented the 
simplified organ microenvironment, in which cells could be seeding into the device and 
integrate themselves into the ECM coated membrane. The future work laid out indicates that 
the scope of this project is truly large and can continue to be examined and studied in the 
nearby future. 
 
 
 
 
 
 
 
